<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">pharmaceutics</journal-id>
      <journal-title-group>
        <journal-title>Pharmaceutics</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Pharmaceutics</abbrev-journal-title>
        <abbrev-journal-title abbrev-type="pubmed">Pharmaceutics</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">1999-4923</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/pharmaceutics15020489</article-id>
      <article-id pub-id-type="publisher-id">pharmaceutics-15-00489</article-id>
      <article-version vocab="JAV" vocab-identifier="https://www.mdpi.com/1999-4923/15/2/489/pdf" vocab-term="Version of Record" article-version-type="VoR">v1</article-version>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Modelling the Evolution of Pore Structure during the Disintegration of Pharmaceutical Tablets</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Soundaranathan</surname>
            <given-names>Mithushan</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
          <xref rid="af1-pharmaceutics-15-00489" ref-type="aff">1</xref>
          <xref rid="af2-pharmaceutics-15-00489" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Al-Sharabi</surname>
            <given-names>Mohammed</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
          <xref rid="af3-pharmaceutics-15-00489" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sweijen</surname>
            <given-names>Thomas</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
          <xref rid="af4-pharmaceutics-15-00489" ref-type="aff">4</xref>
          <xref rid="af5-pharmaceutics-15-00489" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7688-0065</contrib-id>
          <name>
            <surname>Bawuah</surname>
            <given-names>Prince</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
          <xref rid="af3-pharmaceutics-15-00489" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4958-0582</contrib-id>
          <name>
            <surname>Zeitler</surname>
            <given-names>J. Axel</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
          <xref rid="af3-pharmaceutics-15-00489" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6473-9838</contrib-id>
          <name>
            <surname>Hassanizadeh</surname>
            <given-names>S. Majid</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
          <xref rid="af3-pharmaceutics-15-00489" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9796-4150</contrib-id>
          <name>
            <surname>Pitt</surname>
            <given-names>Kendal</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
          <xref rid="af6-pharmaceutics-15-00489" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Johnston</surname>
            <given-names>Blair F.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
          <xref rid="af1-pharmaceutics-15-00489" ref-type="aff">1</xref>
          <xref rid="af2-pharmaceutics-15-00489" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Markl</surname>
            <given-names>Daniel</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
          <xref rid="af1-pharmaceutics-15-00489" ref-type="aff">1</xref>
          <xref rid="af2-pharmaceutics-15-00489" ref-type="aff">2</xref>
          <xref rid="c1-pharmaceutics-15-00489" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Timmins</surname>
            <given-names>Peter</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
      </contrib-group>
      <aff id="af1-pharmaceutics-15-00489"><label>1</label>Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK</aff>
      <aff id="af2-pharmaceutics-15-00489"><label>2</label>Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC), University of Strathclyde, Glasgow G1 1RD, UK</aff>
      <aff id="af3-pharmaceutics-15-00489"><label>3</label>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, UK</aff>
      <aff id="af4-pharmaceutics-15-00489"><label>4</label>Environmental Hydrogeology Group, Department of Earth Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands</aff>
      <aff id="af5-pharmaceutics-15-00489"><label>5</label>CRUX Engineering BV, Pedro de Medinalaan 3c, 1086 XK Amsterdam, The Netherlands</aff>
      <aff id="af6-pharmaceutics-15-00489"><label>6</label>Global Supply Chain, GlaxoSmithKline, Ware SG12 0DE, UK</aff>
      <author-notes>
        <corresp id="c1-pharmaceutics-15-00489"><label>*</label>Correspondence: <email>daniel.markl@strath.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>02</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>02</month>
        <year>2023</year>
      </pub-date>
      <volume>15</volume>
      <issue>2</issue>
      <elocation-id>489</elocation-id>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>11</month>
          <year>2022</year>
        </date>
        <date date-type="rev-recd">
          <day>18</day>
          <month>01</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>01</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2023 by the authors.</copyright-statement>
        <copyright-year>2023</copyright-year>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Pharmaceutical tablet disintegration is a critical process for dissolving and enabling the absorption of the drug substance into the blood stream. The tablet disintegration process consists of multiple connected and interdependent mechanisms: liquid penetration, swelling, dissolution, and break-up. One key dependence is the dynamic change of the pore space in a tablet caused by the swelling of particles while the tablet takes up liquid. This study analysed the changes in the pore structure during disintegration by coupling the discrete element method (DEM) with a single-particle swelling model and experimental liquid penetration data from terahertz-pulsed imaging (TPI). The coupled model is demonstrated and validated for pure microcrystalline cellulose (MCC) tablets across three porosities (10, 15, and 22%) and MCC with three different concentrations of croscarmellose sodium (CCS) (2, 5, and 8% <italic>w</italic>/<italic>w</italic>). The model was validated using experimental tablet swelling from TPI. The model captured the difference in the swelling behaviour of tablets with different porosities and formulations well. Both the experimental and modelling results showed that the swelling was lowest (i.e., time to reach the maximum normalised swelling capacity) for tablets with the highest CCS concentration, <inline-formula><mml:math id="mm1"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%. The simulations revealed that this was caused by the closure of the pores in both the wetted volume and dry volume of the tablet. The closure of the pores hinders the liquid from accessing other particles and slows down the overall swelling process. This study provides new insights into the changes in the pore space during disintegration, which is crucial to better understand the impact of porosity and formulations on the performance of tablets.</p>
      </abstract>
      <kwd-group>
        <kwd>pharmaceutical</kwd>
        <kwd>tablet disintegration</kwd>
        <kwd>swelling</kwd>
        <kwd>discrete element method</kwd>
        <kwd>pore size</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Scottish Research Partnership in Engineering (SRPe)</funding-source>
          <funding-source>National Manufacturing Institute Scotland—Industry Doctorate Programme (NMIS-IDP)</funding-source>
          <award-id>NMIS-IDP/005</award-id>
        </award-group>
        <award-group>
          <funding-source>Future Continuous Manufacturing and Advanced Crystallisation Research Hub</funding-source>
          <award-id>EP/P006965/1</award-id>
        </award-group>
        <award-group>
          <funding-source>Royal Society</funding-source>
          <award-id>RSG/R2/180276</award-id>
        </award-group>
        <award-group>
          <funding-source>U.K. Engineering and Physical Sciences Research Council (EPSRC)</funding-source>
        </award-group>
        <funding-statement>This work was partially funded by the Scottish Research Partnership in Engineering (SRPe): National Manufacturing Institute Scotland—Industry Doctorate Programme (NMIS-IDP) (Project Award Number NMIS-IDP/005). In addition, the authors would like to thank the Future Continuous Manufacturing and Advanced Crystallisation Research Hub (Grant Ref. EP/P006965/1) and the Royal Society (Grant Ref. RSG/R2/180276) for funding this work. We would also like to thank Johnson Matthey and the U.K. Engineering and Physical Sciences Research Council (EPSRC) for funding this work.</funding-statement>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-pharmaceutics-15-00489">
      <title>1. Introduction</title>
      <p>About 90% of orally consumed pharmaceutical products [<xref ref-type="bibr" rid="B1-pharmaceutics-15-00489">1</xref>] are administered in the form of a tablet to deliver the active pharmaceutical ingredient (API) [<xref ref-type="bibr" rid="B2-pharmaceutics-15-00489">2</xref>]. The most-common tablets are manufactured by compacting a formulated powder blend that is composed of one drug substance and a number of different excipients [<xref ref-type="bibr" rid="B3-pharmaceutics-15-00489">3</xref>]. The physical and mechanical properties of tablets, such as porosity and mechanical strength, are significantly affected by the selected formulation and the process conditions used to make the tablet compact [<xref ref-type="bibr" rid="B4-pharmaceutics-15-00489">4</xref>]. The compaction of the powder blend is of critical importance for the particle–particle interaction, as the particles experience intensive deformation during compaction and start to bond together through van der Waals forces, mechanical interlocking, and the formation of solid bridges [<xref ref-type="bibr" rid="B5-pharmaceutics-15-00489">5</xref>].</p>
      <p>The physical properties and mechanical strength of the tablet control its disintegration behaviour, which is critical for dissolving and enabling the absorption of the drug substance into the blood stream. The tablet disintegration process consists of multiple connected and interdependent mechanisms: liquid penetration, swelling, dissolution of excipients and drug, and break-up. The importance of each process depends on the formulation and process conditions used. One of the most-critical processes is the liquid penetration through the porous tablet structure, which initiates the swelling of the particles in the tablet. This swelling builds up an internal stress, which causes the break up of the tablet into smaller agglomerates and primary particles [<xref ref-type="bibr" rid="B6-pharmaceutics-15-00489">6</xref>,<xref ref-type="bibr" rid="B7-pharmaceutics-15-00489">7</xref>]. For the tablet to disintegrate, the internal swelling stress must exceed the strength of the bonds that are formed during compaction [<xref ref-type="bibr" rid="B6-pharmaceutics-15-00489">6</xref>]. The liquid penetration rate is strongly influenced by the tablet porosity, i.e., it generally increases with increasing porosity [<xref ref-type="bibr" rid="B8-pharmaceutics-15-00489">8</xref>]. In many cases, liquid penetration is the controlling mechanism for tablet disintegration, i.e., the time it takes for the tablet to disintegrate highly depends on the liquid uptake. It is important to note that there is a strong interdependence between these different disintegration mechanisms, e.g., particle swelling will cause a change of the pore structure, which will directly affect the liquid penetration process [<xref ref-type="bibr" rid="B6-pharmaceutics-15-00489">6</xref>].</p>
      <p>During the development of a drug product, the formulation and process conditions must be selected to deliver a tablet with the desired properties in terms of its strength, content, and disintegration/dissolution performance. This typically requires a large number of experiments for every new product to explore the relationship between material attributes, process conditions, and performance behaviour in order to identify suitable and robust conditions for the final product. In the last decade, digital design approaches have been developed and deployed to reduce experimental effort and assist in the decision-making throughout the development cycle of new medicines [<xref ref-type="bibr" rid="B9-pharmaceutics-15-00489">9</xref>].</p>
      <p>Wilson et al. [<xref ref-type="bibr" rid="B10-pharmaceutics-15-00489">10</xref>] developed a population model to describe the rate of break-up of a tablet into particles and their size distribution coupled with the Noyes–Whitney equation to predict the dissolution of particles. Masoodi and Pillai [<xref ref-type="bibr" rid="B11-pharmaceutics-15-00489">11</xref>] developed a mathematical model based on Darcy’s law describing the wicking and swelling of paper by considering a dynamic change of porosity. Markl et al. [<xref ref-type="bibr" rid="B12-pharmaceutics-15-00489">12</xref>] modified this model based on an empirical equation from Schott [<xref ref-type="bibr" rid="B13-pharmaceutics-15-00489">13</xref>] for microcrystalline cellulose (MCC) particles to describe the tablet swelling and also the liquid penetration kinetics. Markl et al. [<xref ref-type="bibr" rid="B12-pharmaceutics-15-00489">12</xref>] simplified the swelling of a tablet enlargement in the axial direction only to match their experimental setup. They showed that the capillary radius, <inline-formula><mml:math id="mm2"><mml:semantics><mml:msub><mml:mi>R</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>, decreases with increasing swelling. They assumed that the fractional increase in the volume of the wetted compacted powder was equal to the fractional increase in the volume of a single wetted particle.</p>
      <p>Several studies demonstrated the use of discrete element modelling (DEM) to simulate the tablet compaction process and extract information on the interparticle forces and porosity and other properties affecting the tablet performance [<xref ref-type="bibr" rid="B14-pharmaceutics-15-00489">14</xref>,<xref ref-type="bibr" rid="B15-pharmaceutics-15-00489">15</xref>,<xref ref-type="bibr" rid="B16-pharmaceutics-15-00489">16</xref>,<xref ref-type="bibr" rid="B17-pharmaceutics-15-00489">17</xref>,<xref ref-type="bibr" rid="B18-pharmaceutics-15-00489">18</xref>,<xref ref-type="bibr" rid="B19-pharmaceutics-15-00489">19</xref>,<xref ref-type="bibr" rid="B20-pharmaceutics-15-00489">20</xref>]. DEM is a particle-scale numerical method for modelling the bulk behaviour of granular materials. Many geomaterials such as coal, ores, soil, rocks, aggregates, pellets, tablets, and powders can be described by this method. DEM enables the investigation of the interaction of individual particles and the interparticle effects (stresses, deformation, thermal conductivity, creep). The most-essential element of a DEM model is the underlying particle contact model. The particle contact model is used to calculate the forces acting on particle–particle and particle–wall contacts. Both contact modes can be modelled by the same model. However, the material properties (e.g., coefficient of restitution, friction coefficient, etc.) for each contact type can differ in order to model dissimilar materials. The particle motion is calculated from the force a particle experiences based on these contact models [<xref ref-type="bibr" rid="B21-pharmaceutics-15-00489">21</xref>]. Common contact models applied for tablet compaction simulation include the Luding elasto-plastic model [<xref ref-type="bibr" rid="B22-pharmaceutics-15-00489">22</xref>], Storkers model [<xref ref-type="bibr" rid="B23-pharmaceutics-15-00489">23</xref>], and Hertz–Mindlin theorem [<xref ref-type="bibr" rid="B24-pharmaceutics-15-00489">24</xref>]. Recent studies from [<xref ref-type="bibr" rid="B14-pharmaceutics-15-00489">14</xref>,<xref ref-type="bibr" rid="B25-pharmaceutics-15-00489">25</xref>] showed that the Luding model is suitable for pharmaceutical materials.</p>
      <p>DEM has also been used to model the disintegration process of tablets with the ultimate goal of predicting the drug release [<xref ref-type="bibr" rid="B26-pharmaceutics-15-00489">26</xref>,<xref ref-type="bibr" rid="B27-pharmaceutics-15-00489">27</xref>]. Kalný et al. [<xref ref-type="bibr" rid="B27-pharmaceutics-15-00489">27</xref>] simulated the disintegration and dissolution of a two-component tablet with ibuprofen as the API and croscarmellose sodium (CCS) as a disintegrant. They assumed that only the CCS particles contribute to the total swelling and the swelling was only occurring in the axial direction. They simplified the swelling by assuming that all particles swell simultaneously and at a constant rate, i.e., the liquid penetration behaviour was not considered. Reference [<xref ref-type="bibr" rid="B26-pharmaceutics-15-00489">26</xref>] developed a model for simulating the swelling and dissolution process of a polymer tablet by incorporating the Fickian diffusion of water into a particle in their DEM model. The particle was assumed to be cylindrical with swelling only occurring in the radial direction. Schtt et al. [<xref ref-type="bibr" rid="B28-pharmaceutics-15-00489">28</xref>] developed a model to simulate tablet disintegration in the human ascending colon using a discrete multiphysics approach coupled with a smoothed particle hydrodynamics and lattice spring model.</p>
      <p>Studies from other fields, such as hydrogeology [<xref ref-type="bibr" rid="B29-pharmaceutics-15-00489">29</xref>,<xref ref-type="bibr" rid="B30-pharmaceutics-15-00489">30</xref>], have used DEM to simulate similar processes. Reference [<xref ref-type="bibr" rid="B29-pharmaceutics-15-00489">29</xref>] and Reference [<xref ref-type="bibr" rid="B30-pharmaceutics-15-00489">30</xref>] applied DEM to simulate the swelling of superabsorbent polymer particles (SAPs) with an integrated liquid penetration model. Reference [<xref ref-type="bibr" rid="B29-pharmaceutics-15-00489">29</xref>] simulated the swelling of a bed of SAPs using a single-particle swelling model combined with the pore finite volume method to model the liquid flow in the compacts. They developed this model further [<xref ref-type="bibr" rid="B30-pharmaceutics-15-00489">30</xref>], where the unsaturated flow was computed using a scheme of an implicit pressure solver and an explicit saturation update. Reference Braile et al. [<xref ref-type="bibr" rid="B31-pharmaceutics-15-00489">31</xref>] developed a DEM model for the swelling of granular materials (MCC PH101, rice, and superabsorbent particles), and they simulated the swelling of the material using the first-order kinetics equation to model the swelling of single particles and the materials soaking in water.</p>
      <p>In existing studies on tablet disintegration, the pore structure change during the disintegration process and the effect of the dynamically changing pore structure on the disintegration time are not fully understood. This study assessed the changes in the pore structure during disintegration by coupling DEM with a single-particle swelling model and experimental liquid penetration data. First, the compaction of the powders were simulated using DEM with the Luding contact model [<xref ref-type="bibr" rid="B22-pharmaceutics-15-00489">22</xref>]. This delivers a 3D discrete element model of the tablet, which is then used to simulate the tablet swelling utilising a single-particle swelling model [<xref ref-type="bibr" rid="B32-pharmaceutics-15-00489">32</xref>]. The use of the coupled model is demonstrated for pure MCC tablets with three porosities and MCC with three different concentrations of CCS. The model was validated against the experimental results.</p>
    </sec>
    <sec id="sec2-pharmaceutics-15-00489">
      <title>2. Materials and Methods</title>
      <sec sec-type="materials" id="sec2dot1-pharmaceutics-15-00489">
        <title>2.1. Materials</title>
        <p>The materials analysed in this study included MCC PH101 (Avicel PH101, Roquette, Lestrem, France) and the disintegrant croscarmellose sodium (Ac-Di-Sol, CCS, SDW-802, FMC International, Philadelphia, PA, USA). MCC, in particular grade PH101, was selected as a model compound as it is one of the most commonly used excipients in the pharmaceutical industry. The values of particles’ properties are given in <xref ref-type="table" rid="pharmaceutics-15-00489-t001">Table 1</xref> and <xref ref-type="table" rid="pharmaceutics-15-00489-t002">Table 2</xref>. The particle size and sphericity were measured by QICPIC (Sympatec GmbH, Clausthal-Zellerfeld, Germany). The true density of the material was measured by a helium pycnometer (MicroUltrapyc 1200, Quantachrome instrument, Graz, Austria).</p>
      </sec>
      <sec sec-type="methods" id="sec2dot2-pharmaceutics-15-00489">
        <title>2.2. Experimental</title>
        <sec id="sec2dot2dot1-pharmaceutics-15-00489">
          <title>2.2.1. Tablet Compaction</title>
          <p>These tablet were prepared via direct compression using a compaction simulator (HB50, Huxley-Bertram Engineering, Cambridge, UK). The samples had a diameter of 10 mm and a thickness around 2 mm. The diameter and thickness were kept constant, while the filling weight of the powder material was adjusted to vary the tablet porosity. The powder was filled manually into the die of the compaction simulator to achieve precise powder filling. The compaction process was performed using a sinusoidal compaction profile, with an average speed of 0.026 m/s. The formulations of the tablets, the compression pressure, and the porosity values are given in <xref ref-type="table" rid="pharmaceutics-15-00489-t003">Table 3</xref>.</p>
        </sec>
        <sec id="sec2dot2dot2-pharmaceutics-15-00489">
          <title>2.2.2. Liquid Penetration and Tablet Swelling</title>
          <p>The liquid penetration and tablet swelling were measured using a commercial terahertz-pulsed imaging system (TPI, TeraPulse 4000, Teraview Ltd., Cambridge, UK) in combination with a bespoke flow cell [<xref ref-type="bibr" rid="B33-pharmaceutics-15-00489">33</xref>]. The TPI was set up with a fibre-based reflection probe equipped with an 18 mm focal-length silicon lens. The probe head was on a linear scale for the ease of spatial adjustment. The beam resulting from the THz optics had a beam waist of around 1 mm at the focus with an incident angle of 13°. The TPI setup with the flow cell (<xref ref-type="fig" rid="pharmaceutics-15-00489-f001">Figure 1</xref>a) measures the change of the back face of the tablet, which reflects the swelling of both the back face and the front face, where the liquid uptake occurs. Since the flow cell was not included in the DEM simulation (<xref ref-type="fig" rid="pharmaceutics-15-00489-f001">Figure 1</xref>b), only the front face swelling was recorded in the simulation. More details about the flow cell and its design can be foundin [<xref ref-type="bibr" rid="B33-pharmaceutics-15-00489">33</xref>].</p>
        </sec>
      </sec>
      <sec id="sec2dot3-pharmaceutics-15-00489">
        <title>2.3. Modelling</title>
        <p><xref ref-type="fig" rid="pharmaceutics-15-00489-f002">Figure 2</xref> depicts a diagram summarising the integration of the models and experimental data to simulate tablet swelling and break-up. The tablet swelling and break-up model consists of three main parts: (1) tablet compaction model in DEM, (2) disintegration model in DEM with a single-particle swelling model [<xref ref-type="bibr" rid="B32-pharmaceutics-15-00489">32</xref>], and (3) experimental liquid penetration data. Both compaction and disintegration models were implemented in the open-source DEM software Yade-DEM [<xref ref-type="bibr" rid="B34-pharmaceutics-15-00489">34</xref>].</p>
        <sec id="sec2dot3dot1-pharmaceutics-15-00489">
          <title>2.3.1. Tablet Compaction</title>
          <p>The compaction process was simulated by compressing the particles, which were assumed to be spherical under gravity, to a loose, random packing in a cylindrical compression die with a height of 3 mm and a radius of 1 mm. To decrease the computational cost, the simulated tablet was scaled down to a diameter of 2 mm and a thickness of 0.8–1 mm while using the experimental particle size distribution (<xref ref-type="table" rid="pharmaceutics-15-00489-t002">Table 2</xref>) in the DEM. The concentration of each material, the compression force, and the punch speed were set according to the experimental setup described in <xref ref-type="sec" rid="sec2dot2dot1-pharmaceutics-15-00489">Section 2.2.1</xref> and <xref ref-type="table" rid="pharmaceutics-15-00489-t003">Table 3</xref>. The number of particles simulated for each formulation is given in <xref ref-type="table" rid="pharmaceutics-15-00489-t004">Table 4</xref>. The compression force and porosity were recorded during the simulation.</p>
          <p>The Luding elasto-plastic contact model [<xref ref-type="bibr" rid="B22-pharmaceutics-15-00489">22</xref>] was applied for particle–particle and particle–wall interactions; the model is given in Equations (<xref ref-type="disp-formula" rid="FD1-pharmaceutics-15-00489">1</xref>)–(<xref ref-type="disp-formula" rid="FD3-pharmaceutics-15-00489">3</xref>). The force in the normal direction, <inline-formula><mml:math id="mm4"><mml:semantics><mml:msub><mml:mi mathvariant="bold">F</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>, is given as
          <disp-formula id="FD1-pharmaceutics-15-00489"><label>(1)</label><mml:math id="mm5" display="block"><mml:semantics><mml:mrow><mml:msub><mml:mi mathvariant="bold">F</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfenced separators="" open="{" close=""><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="1.em"/><mml:mi>if</mml:mi><mml:mspace width="4.pt"/><mml:msub><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>≥</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="1.em"/><mml:mi>if</mml:mi><mml:mspace width="4.pt"/><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>≥</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:msub><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:msub><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="1.em"/><mml:mi>if</mml:mi><mml:mspace width="4.pt"/><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:msub><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mfenced></mml:mrow></mml:semantics></mml:math></disp-formula>
          with <inline-formula><mml:math id="mm6"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> as the loading stiffness, <inline-formula><mml:math id="mm7"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> as the plastic unloading stiffness, <inline-formula><mml:math id="mm8"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> as the adhesion stiffness, <inline-formula><mml:math id="mm9"><mml:semantics><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> as the normal overlap, and <inline-formula><mml:math id="mm10"><mml:semantics><mml:msub><mml:mi>δ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> as the plastic contact deformation overlap. <inline-formula><mml:math id="mm11"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> is defined as: <disp-formula id="FD2-pharmaceutics-15-00489"><label>(2)</label><mml:math id="mm12" display="block"><mml:semantics><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mfenced separators="" open="{" close=""><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="1.em"/><mml:mi>if</mml:mi><mml:mspace width="4.pt"/><mml:msub><mml:mi>δ</mml:mi><mml:mi>max</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>lim</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>max</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>lim</mml:mi></mml:msub></mml:mfrac></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="1.em"/><mml:mi>if</mml:mi><mml:mspace width="4.pt"/><mml:msub><mml:mi>δ</mml:mi><mml:mi>max</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>lim</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mfenced></mml:mrow></mml:semantics></mml:math></disp-formula>
          where <inline-formula><mml:math id="mm13"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> is the limit plastic unloading stiffness. <inline-formula><mml:math id="mm14"><mml:semantics><mml:msub><mml:mi>δ</mml:mi><mml:mi>max</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> and <inline-formula><mml:math id="mm15"><mml:semantics><mml:msub><mml:mi>δ</mml:mi><mml:mi>lim</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> (see Equation (<xref ref-type="disp-formula" rid="FD3-pharmaceutics-15-00489">3</xref>)) are the maximum compression overlap and the plastic limit, respectively.
          <disp-formula id="FD3-pharmaceutics-15-00489"><label>(3)</label><mml:math id="mm16" display="block"><mml:semantics><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>lim</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:semantics></mml:math></disp-formula>
          where <inline-formula><mml:math id="mm17"><mml:semantics><mml:msub><mml:mi>ϕ</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> is the dimensionless plasticity depth and <inline-formula><mml:math id="mm18"><mml:semantics><mml:msup><mml:mi>R</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:semantics></mml:math></inline-formula> is an equivalent radius. The values of the parameters used in this study are given in <xref ref-type="table" rid="pharmaceutics-15-00489-t005">Table 5</xref>.</p>
          <p>Reference [<xref ref-type="bibr" rid="B14-pharmaceutics-15-00489">14</xref>] showed that the parameters <inline-formula><mml:math id="mm19"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> (loading stiffness) and <inline-formula><mml:math id="mm20"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> (limit plastic unloading stiffness) of the Luding elasto-plastic model and the particle density impacted the compression profile mostly and the adjustment of these three parameters could cover most of the variations of the compression profile. As [<xref ref-type="bibr" rid="B14-pharmaceutics-15-00489">14</xref>] increased the particle size in the model compared to the experiments, they accounted for this in the model by calibrating the particle density. In this work, the particle size in the model was the same as in the experiments, and hence, the measured particle (true) density was used for the simulations.</p>
          <p>The two unknown parameters in the model, <inline-formula><mml:math id="mm21"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> and <inline-formula><mml:math id="mm22"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>, were determined through an optimisation procedure that minimises the error between the porosity values calculated from the DEM model and the experimental data. For the pure MCC tablets, this was performed for the medium compression pressure (15% porosity tablets) and was validated using the data from the experiments with low- and high-compression pressure. The calibration method was based on the work of [<xref ref-type="bibr" rid="B14-pharmaceutics-15-00489">14</xref>]. As <inline-formula><mml:math id="mm23"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> only affects the loading stage of the compaction process, the process was simulated for various different values of <inline-formula><mml:math id="mm24"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>, ranging from 500 to 20,000 N/m, simultaneously using the batch simulation mode in Yade. The root-mean-squared error (RMSE) between the experimental tablet porosity and simulated tablet porosity during loading for various <inline-formula><mml:math id="mm25"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> values was minimised to identify the optimal value. Reference [<xref ref-type="bibr" rid="B19-pharmaceutics-15-00489">19</xref>] highlighted that the difference between initial experimental porosity and that of a simulated DEM tablet is primarily caused by the deviation of the real particle shape from the assumed spherical shape in the DEM. Other factors affecting the initial packing of the powder such as intra-particle porosity and surface asperities were also not considered in the DEM. This difference in initial porosity caused an error in the estimation of <inline-formula><mml:math id="mm26"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>. To minimise the effect of this initial difference in the packing of the powder, the porosity in the loading process was scaled to a value between 0 (minimum observed porosity) and 1 (maximum observed porosity) and the calculated RMSE values were used to determine the optimal <inline-formula><mml:math id="mm27"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> value. This scaling significantly improves the estimation of <inline-formula><mml:math id="mm28"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> as this parameter primarily controls the curvature of the loading profile. <inline-formula><mml:math id="mm29"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> was calibrated using the optimised <inline-formula><mml:math id="mm30"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> value, and we simulated the process again at different <inline-formula><mml:math id="mm31"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> to reach the final desired tablet porosity.</p>
        </sec>
        <sec id="sec2dot3dot2-pharmaceutics-15-00489">
          <title>2.3.2. Disintegration Model</title>
          <p>The simulations of the swelling of the tablets modelled in <xref ref-type="sec" rid="sec2dot3dot1-pharmaceutics-15-00489">Section 2.3.1</xref> was set up to closely mimic the experimental work described. The time step (<inline-formula><mml:math id="mm32"><mml:semantics><mml:mrow><mml:mo>Δ</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:semantics></mml:math></inline-formula>) was set at <inline-formula><mml:math id="mm33"><mml:semantics><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:semantics></mml:math></inline-formula> s/step to ensure simulation stability. The radius, mass, and inertia of individual particles were updated according to a single-particle swelling model (Equations (<xref ref-type="disp-formula" rid="FD4-pharmaceutics-15-00489">4</xref>)–(<xref ref-type="disp-formula" rid="FD12-pharmaceutics-15-00489">12</xref>)). Reference [<xref ref-type="bibr" rid="B29-pharmaceutics-15-00489">29</xref>] originally derived this model to describe the swelling process of SAPs. The model assumes that the swelling of a particle is driven by the difference in the chemical potential between the particle and water (liquid medium) [<xref ref-type="bibr" rid="B36-pharmaceutics-15-00489">36</xref>]. The single-particle swelling model is given as follows: <disp-formula id="FD4-pharmaceutics-15-00489"><label>(4)</label><mml:math id="mm34" display="block"><mml:semantics><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi mathvariant="normal">w</mml:mi></mml:msub><mml:mfrac><mml:mrow><mml:mi>D</mml:mi><mml:msub><mml:mi>ϱ</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>ϱ</mml:mi><mml:mi mathvariant="normal">w</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mfenced open="(" close=")"><mml:mfrac><mml:mrow><mml:msup><mml:mi>Q</mml:mi><mml:mi>max</mml:mi></mml:msup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mi>abs</mml:mi></mml:msubsup></mml:mrow><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mi>abs</mml:mi></mml:msubsup></mml:mfrac></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula>
          <disp-formula id="FD5-pharmaceutics-15-00489"><label>(5)</label><mml:math id="mm35" display="block"><mml:semantics><mml:mrow><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mi>abs</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>m</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mi mathvariant="normal">w</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>m</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:msubsup></mml:mrow><mml:msubsup><mml:mi>m</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:msubsup></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>r</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:mrow><mml:mn>3</mml:mn></mml:msubsup><mml:msub><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">w</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>r</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow><mml:mn>3</mml:mn></mml:msubsup><mml:msub><mml:mi>ϱ</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>ϱ</mml:mi><mml:mi mathvariant="normal">w</mml:mi></mml:msub><mml:msub><mml:mi>ϱ</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo></mml:mrow></mml:semantics></mml:math></disp-formula>
          where <inline-formula><mml:math id="mm36"><mml:semantics><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:semantics></mml:math></inline-formula> is the initial particle radius, <inline-formula><mml:math id="mm37"><mml:semantics><mml:msub><mml:mi>r</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> is the particle radius at time <italic>t</italic>, <inline-formula><mml:math id="mm38"><mml:semantics><mml:msub><mml:mi>ϱ</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> is the density of a dry particle, and <inline-formula><mml:math id="mm39"><mml:semantics><mml:msub><mml:mi>ϱ</mml:mi><mml:mi mathvariant="normal">w</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> is the density of the liquid (deionised water in this study). <italic>D</italic> (<inline-formula><mml:math id="mm40"><mml:semantics><mml:mi mathvariant="sans-serif">μ</mml:mi></mml:semantics></mml:math></inline-formula>m<inline-formula><mml:math id="mm41"><mml:semantics><mml:msup><mml:mrow/><mml:mn>2</mml:mn></mml:msup></mml:semantics></mml:math></inline-formula>/s) is the diffusion coefficient for water molecules in the particle, which was assumed to be constant. <inline-formula><mml:math id="mm42"><mml:semantics><mml:msup><mml:mi>Q</mml:mi><mml:mi>max</mml:mi></mml:msup></mml:semantics></mml:math></inline-formula> is the maximum absorption ratio. The values of <italic>D</italic> (<inline-formula><mml:math id="mm43"><mml:semantics><mml:mi mathvariant="sans-serif">μ</mml:mi></mml:semantics></mml:math></inline-formula>m<inline-formula><mml:math id="mm44"><mml:semantics><mml:msup><mml:mrow/><mml:mn>2</mml:mn></mml:msup></mml:semantics></mml:math></inline-formula>/s) and <inline-formula><mml:math id="mm45"><mml:semantics><mml:msup><mml:mi>Q</mml:mi><mml:mi>max</mml:mi></mml:msup></mml:semantics></mml:math></inline-formula> for the various materials used in this study were taken from [<xref ref-type="bibr" rid="B32-pharmaceutics-15-00489">32</xref>] and are given in <xref ref-type="table" rid="pharmaceutics-15-00489-t001">Table 1</xref>.</p>
          <p>This model assumes that the entire particle is exposed to the liquid, which is not valid when the particle is part of a compact tablet. In a compact tablet, particles form bonds with neighbouring particles across a contact area. This reduces the effective (available) surface area of the particle that is exposed to the absorbing liquid. This is accounted for by introducing the factor <inline-formula><mml:math id="mm46"><mml:semantics><mml:msub><mml:mi>f</mml:mi><mml:mi mathvariant="normal">w</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> in Equation (<xref ref-type="disp-formula" rid="FD4-pharmaceutics-15-00489">4</xref>) that describes the fraction of the available surface (<inline-formula><mml:math id="mm47"><mml:semantics><mml:msub><mml:mi>A</mml:mi><mml:mi>actual</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>) to the total particle surface area (<inline-formula><mml:math id="mm48"><mml:semantics><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>4</mml:mn><mml:mi>π</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:mrow></mml:semantics></mml:math></inline-formula>).
          <disp-formula id="FD6-pharmaceutics-15-00489"><label>(6)</label><mml:math id="mm49" display="block"><mml:semantics><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi mathvariant="normal">w</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>A</mml:mi><mml:mi>actual</mml:mi></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula></p>
          <p><inline-formula><mml:math id="mm50"><mml:semantics><mml:msub><mml:mi>A</mml:mi><mml:mi>actual</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> is defined as the particle surface area subtracted by the sum of the overlapping area with neighbouring particles: <disp-formula id="FD7-pharmaceutics-15-00489"><label>(7)</label><mml:math id="mm51" display="block"><mml:semantics><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mi>actual</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>cap</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula></p>
          <p><inline-formula><mml:math id="mm52"><mml:semantics><mml:msub><mml:mi>A</mml:mi><mml:mi>cap</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> is the surface area of the normal displaced volume between two neighbouring particles, particles <italic>i</italic> and <italic>j</italic>, and defined as a function of the particle, centroid <italic>i</italic>, <inline-formula><mml:math id="mm53"><mml:semantics><mml:msub><mml:mi>x</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>, <inline-formula><mml:math id="mm54"><mml:semantics><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>, <inline-formula><mml:math id="mm55"><mml:semantics><mml:msub><mml:mi>z</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>, and the coordinate of the contact point between particles <italic>i</italic> and <italic>j</italic> (<inline-formula><mml:math id="mm56"><mml:semantics><mml:msub><mml:mi>x</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>, <inline-formula><mml:math id="mm57"><mml:semantics><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>, <inline-formula><mml:math id="mm58"><mml:semantics><mml:msub><mml:mi>z</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>). <italic>n</italic> is the number of neighbouring particles. <inline-formula><mml:math id="mm59"><mml:semantics><mml:msub><mml:mi>A</mml:mi><mml:mi>cap</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> is given as
          <disp-formula id="FD8-pharmaceutics-15-00489"><label>(8)</label><mml:math id="mm60" display="block"><mml:semantics><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mi>cap</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mi>h</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula>
          with <italic>h</italic> as the height of the overlapping cap, defined as
          <disp-formula id="FD9-pharmaceutics-15-00489"><label>(9)</label><mml:math id="mm61" display="block"><mml:semantics><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>h</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msqrt><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msqrt><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula></p>
          <p>The position of the liquid was also updated every 100,000th time step using the experimental data. As the time instances of the experimental liquid penetration data did not match the simulation time points, a power law (<inline-formula><mml:math id="mm62"><mml:semantics><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mi>a</mml:mi><mml:mo>·</mml:mo><mml:msup><mml:mi>t</mml:mi><mml:mi>b</mml:mi></mml:msup></mml:mrow></mml:semantics></mml:math></inline-formula>) was fit to the experimental results from <xref ref-type="sec" rid="sec2dot2dot2-pharmaceutics-15-00489">Section 2.2.2</xref>, enabling the calculation of the liquid front position in the tablet at the simulation time points. The fitting parameters for all formulations are shown in <xref ref-type="table" rid="pharmaceutics-15-00489-t006">Table 6</xref>. The simulation of a single-particle swelling assumes that a particle starts to swell once the liquid reaches the particle centre; the model than considers the available wetted surface area to be <inline-formula><mml:math id="mm63"><mml:semantics><mml:msub><mml:mi>A</mml:mi><mml:mi>actual</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>. The particle size change was implemented in the DEM by defining a growth factor (<italic>f</italic>): <disp-formula id="FD10-pharmaceutics-15-00489"><label>(10)</label><mml:math id="mm64" display="block"><mml:semantics><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>f</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>Δ</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>M</mml:mi><mml:mo>Δ</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula></p>
          <p>To accelerate the simulation, the particle radius, mass, and inertia were updated only every 100,000th time step (M = 100,000). <inline-formula><mml:math id="mm65"><mml:semantics><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>Δ</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:semantics></mml:math></inline-formula> is the radius at time <inline-formula><mml:math id="mm66"><mml:semantics><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>Δ</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:semantics></mml:math></inline-formula>. Due to the absorption of the liquid by the particle, the mass (<italic>m</italic>) and inertia (<italic>J</italic>) of a particle were also updated:  <disp-formula id="FD11-pharmaceutics-15-00489"><label>(11)</label><mml:math id="mm67" display="block"><mml:semantics><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>m</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>Δ</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:mo>=</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>·</mml:mo><mml:msup><mml:mi>f</mml:mi><mml:mn>3</mml:mn></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula><disp-formula id="FD12-pharmaceutics-15-00489"><label>(12)</label><mml:math id="mm68" display="block"><mml:semantics><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>J</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>Δ</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:mo>=</mml:mo><mml:mi>J</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>·</mml:mo><mml:msup><mml:mi>f</mml:mi><mml:mn>5</mml:mn></mml:msup><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula></p>
          <p>The entire workflow to simulate the tablet swelling and break-up is presented in <xref ref-type="fig" rid="pharmaceutics-15-00489-f003">Figure 3</xref>.</p>
        </sec>
        <sec id="sec2dot3dot3-pharmaceutics-15-00489">
          <title>2.3.3. Pore Structure Analysis of DEM Results</title>
          <p>The porosity was measured using the voxel porosity method [<xref ref-type="bibr" rid="B34-pharmaceutics-15-00489">34</xref>]. This approach divides the whole volume into a dense grid of voxels at a given resolution (resolution = 200 <inline-formula><mml:math id="mm69"><mml:semantics><mml:mi mathvariant="sans-serif">μ</mml:mi></mml:semantics></mml:math></inline-formula>m) and counts the voxels that fall inside any of the particles. The porosity, <inline-formula><mml:math id="mm70"><mml:semantics><mml:mi>ϵ</mml:mi></mml:semantics></mml:math></inline-formula>, is calculated as
          <disp-formula id="FD13-pharmaceutics-15-00489"><label>(13)</label><mml:math id="mm71" display="block"><mml:semantics><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>ϵ</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>V</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mi mathvariant="normal">v</mml:mi></mml:msub></mml:mrow><mml:mi>V</mml:mi></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula>
          where <italic>V</italic> is volume of the tablet and <inline-formula><mml:math id="mm72"><mml:semantics><mml:msub><mml:mi>V</mml:mi><mml:mi mathvariant="normal">v</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> is the volume of voxels that fall inside any particles.</p>
          <p>The pore sizes were determined using the triangulation and pore finite volume method described in [<xref ref-type="bibr" rid="B37-pharmaceutics-15-00489">37</xref>] and subsequently [<xref ref-type="bibr" rid="B29-pharmaceutics-15-00489">29</xref>]. First, a triangulation procedure was applied to the pore space of the tablet using solid particle centres as vertices for the tetrahedra. The tetrahedron spans across four neighbouring particles and defines the pore space. This is referred to as a pore unit. The size of each pore unit in the tablet was then calculated as the radius of inscribed circle of the tetrahedron.</p>
          <p>Cumulative porosity maps were generated to analyse the pore space spatially. This method is described in detail in [<xref ref-type="bibr" rid="B38-pharmaceutics-15-00489">38</xref>]. In brief, PoreSpy [<xref ref-type="bibr" rid="B39-pharmaceutics-15-00489">39</xref>] was used to generate a 3D voxel image of the tablet based on particles’ position and radius. A cuboid subsection (1400 × 1400 × 800 <inline-formula><mml:math id="mm73"><mml:semantics><mml:mi mathvariant="sans-serif">μ</mml:mi></mml:semantics></mml:math></inline-formula>m<inline-formula><mml:math id="mm74"><mml:semantics><mml:msup><mml:mrow/><mml:mn>3</mml:mn></mml:msup></mml:semantics></mml:math></inline-formula>) of the voxel image at the centre of the tablet was selected for this analysis. The maps were obtained by dividing the sum of the number of voxels classified as voids along each dimension (<italic>x</italic>, <italic>y</italic>, and <italic>z</italic>) by the total number of voxels per dimension. The generated maps depict the void fraction at each position.</p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3-pharmaceutics-15-00489">
      <title>3. Results and Discussion</title>
      <sec id="sec3dot1-pharmaceutics-15-00489">
        <title>3.1. Tablet Compaction and Parameter Calibration</title>
        <p>The pure MCC PH101 tablet at the three different porosities and the tablet with MCC and CCS followed a very similar trend in the loading and unloading stage of the compression (<xref ref-type="fig" rid="pharmaceutics-15-00489-f004">Figure 4</xref>). The parameters <inline-formula><mml:math id="mm75"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> and <inline-formula><mml:math id="mm76"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> were thus calibrated for the MCC PH101 tablet with <inline-formula><mml:math id="mm77"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> and validated using the profiles of other conditions. <xref ref-type="fig" rid="pharmaceutics-15-00489-f005">Figure 5</xref>a shows the comparison between the experimental and simulated compression profiles for an MCC PH101 tablet with <inline-formula><mml:math id="mm78"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula>. As discussed in <xref ref-type="sec" rid="sec2dot3dot2-pharmaceutics-15-00489">Section 2.3.2</xref>, the deviation from the measured value (<inline-formula><mml:math id="mm79"><mml:semantics><mml:mrow><mml:mi>ε</mml:mi><mml:mo>=</mml:mo><mml:mn>0.56</mml:mn></mml:mrow></mml:semantics></mml:math></inline-formula> at <inline-formula><mml:math id="mm80"><mml:semantics><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:semantics></mml:math></inline-formula>) and of the DEM initial porosity (<inline-formula><mml:math id="mm81"><mml:semantics><mml:mrow><mml:mi>ε</mml:mi><mml:mo>=</mml:mo><mml:mn>0.44</mml:mn></mml:mrow></mml:semantics></mml:math></inline-formula> at <inline-formula><mml:math id="mm82"><mml:semantics><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:semantics></mml:math></inline-formula>) influenced the parameter estimation. A scaling procedure was applied to minimise the error caused by this discrepancy. The scaled loading profiles (<xref ref-type="fig" rid="pharmaceutics-15-00489-f005">Figure 5</xref>b) followed similar trends, which enabled an accurate determination of <inline-formula><mml:math id="mm83"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>.</p>
        <p>The optimisation procedure with the scaled porosity profiles of a PH101 tablet with <inline-formula><mml:math id="mm84"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> yielded <inline-formula><mml:math id="mm85"><mml:semantics><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>10,000</mml:mn></mml:mrow></mml:semantics></mml:math></inline-formula> N/m, which in turn resulted in a <inline-formula><mml:math id="mm86"><mml:semantics><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>140,000</mml:mn></mml:mrow></mml:semantics></mml:math></inline-formula> N/m to reach the final target porosity (<xref ref-type="table" rid="pharmaceutics-15-00489-t007">Table 7</xref>). The parameters were validated for MCC PH101 <inline-formula><mml:math id="mm87"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> 10 and 22% and MCC PH101, as well as MCC/CCS tablets with <inline-formula><mml:math id="mm88"><mml:semantics><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> 2, 5, and 8% (<xref ref-type="fig" rid="pharmaceutics-15-00489-f005">Figure 5</xref>c,d). The DEM loading profiles followed the validation experiments closely, and the final porosity values obtained from the DEM simulation were in excellent agreement with the experimental values (<xref ref-type="table" rid="pharmaceutics-15-00489-t008">Table 8</xref>).</p>
      </sec>
      <sec id="sec3dot2-pharmaceutics-15-00489">
        <title>3.2. Experimental Tablet Swelling and Liquid Penetration Data Analysis</title>
        <p>The uni-directional liquid penetration profile was determined experimentally. As the experimental time instances did not match the simulation time instances, a power law (<inline-formula><mml:math id="mm89"><mml:semantics><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mi>a</mml:mi><mml:mo>·</mml:mo><mml:msup><mml:mi>t</mml:mi><mml:mi>b</mml:mi></mml:msup></mml:mrow></mml:semantics></mml:math></inline-formula>) was fit to each experimental dataset. The power law was then evaluated at the simulation time points to retrieve the liquid position. The fit power law parameters for all formulations studied are given in <xref ref-type="table" rid="pharmaceutics-15-00489-t006">Table 6</xref>.</p>
        <p>The swelling profiles for six different conditions were simulated using the DEM with a single-particle swelling model and experimental liquid penetration depth data (<xref ref-type="fig" rid="pharmaceutics-15-00489-f006">Figure 6</xref>). To account for the effect of differences in thickness, <inline-formula><mml:math id="mm90"><mml:semantics><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>, between the DEM and the experimental tablet, the swelling profiles and the time were normalised. Each swelling profile was divided by its maximum. The time was normalised, <inline-formula><mml:math id="mm91"><mml:semantics><mml:msup><mml:mi>T</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:semantics></mml:math></inline-formula>, using Equation (<xref ref-type="disp-formula" rid="FD14-pharmaceutics-15-00489">14</xref>) [<xref ref-type="bibr" rid="B29-pharmaceutics-15-00489">29</xref>].
        <disp-formula id="FD14-pharmaceutics-15-00489"><label>(14)</label><mml:math id="mm92" display="block"><mml:semantics><mml:mrow><mml:msup><mml:mi>T</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>t</mml:mi><mml:mo>·</mml:mo><mml:mi>D</mml:mi></mml:mrow><mml:msubsup><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:semantics></mml:math></disp-formula></p>
        <p>As seen from <xref ref-type="fig" rid="pharmaceutics-15-00489-f006">Figure 6</xref>, PH101 with <inline-formula><mml:math id="mm93"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>22</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> swelled the fastest both in the DEM and experimentally, followed by <inline-formula><mml:math id="mm94"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> and <inline-formula><mml:math id="mm95"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>10</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula>. The experimental and DEM swelling data were generally in very good agreement (<xref ref-type="fig" rid="pharmaceutics-15-00489-f006">Figure 6</xref>a). Both measured and DEM swelling profiles reached their maximum capacity at approximately the same time, indicating that the model captured the difference in swelling time for various tablets very well. Similar to the PH101 results, the simulated and experimental swelling profile of PH101/CCS (<xref ref-type="fig" rid="pharmaceutics-15-00489-f006">Figure 6</xref>b) reached the maximum swelling capacity at approximately the same time for <inline-formula><mml:math id="mm96"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 2% and PH101/CCS, <inline-formula><mml:math id="mm97"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%, while for <inline-formula><mml:math id="mm98"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 5%, the experimental swelling was faster.</p>
        <p>The swelling profiles of the experiments and DEM followed different trends though. This was mainly attributed to: (1) limited consideration of the bonding types and compaction mechanisms in DEM, (2) the assumption of a spherical particle shape in the DEM, and (3) differences between the experimental flow cell and simulation setup.</p>
        <p>Firstly, the bonds present in an MCC tablet are due to intermolecular forces such as Van der Waals force and hydrogen bonds, solid bridges, and mechanical interlocking [<xref ref-type="bibr" rid="B40-pharmaceutics-15-00489">40</xref>]. In particular, the mechanical interlocking was not captured in the DEM simulation. Compaction phenomena such as deformation and fragmentation during compaction were also not considered in the DEM model. Reference [<xref ref-type="bibr" rid="B18-pharmaceutics-15-00489">18</xref>] developed a method to account for the deformation during compaction. However, this was not considered at this stage as this would yield non-spherical particles in the final DEM tablet. Secondly, the single-particle swelling model was designed for spheres for simplicity and computational efficiency reasons. This is an approximation for the raw materials, as it is known that PH101 and CCS are typically non-spherical particles with a sphericity in the range of 0.66 to 0.73. The effect of the non-spherical shape on the anisotropic swelling process was discussed in [<xref ref-type="bibr" rid="B32-pharmaceutics-15-00489">32</xref>]. Thirdly, the TPI setup with the flow cell measured the change of the back face of the tablet, which reflects the swelling on both the back face and on the front face, where it takes up the liquid [<xref ref-type="bibr" rid="B8-pharmaceutics-15-00489">8</xref>]. The front face swelling lifts the tablet off the sample holder, causing the observed change of the back face tablet, as captured in the experimental data. As the sample holder was not included in the DEM setup, only the front face swelling was recorded in the simulation.</p>
      </sec>
      <sec id="sec3dot3-pharmaceutics-15-00489">
        <title>3.3. Analysis of Time-Dependent Pore Space</title>
        <p>The swelling behaviour is primarily driven by the liquid penetration rate. The liquid penetration is strongly impacted by the change of the pore space caused by the swelling of particles. Both the pore space behind and ahead of the liquid front can change during the liquid uptake process. The data from the DEM simulations enabled the analysis of this in detail.</p>
        <sec id="sec3dot3dot1-pharmaceutics-15-00489">
          <title>3.3.1. Pore Space of Entire Tablet</title>
          <p><xref ref-type="fig" rid="pharmaceutics-15-00489-f007">Figure 7</xref>a,c show the porosity change during the swelling of the tablets for both the overall tablet and only the wetted volume. The initial delay in the porosity measurement for the wetted volume was due to the analysed volume being too small to be accurately measured and representative. The porosity decreased initially during the swelling of the wetted volume (<xref ref-type="fig" rid="pharmaceutics-15-00489-f007">Figure 7</xref>a). This was observed for PH101 tablets with <inline-formula><mml:math id="mm99"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> and <inline-formula><mml:math id="mm100"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>22</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula>, indicating that the pores were closing in the initial stages of the swelling process. After the initial decrease, the porosity increased for both the wetted volume and the whole tablet. This increase was primarily attributed to the fact that the tablets were eroding, i.e., individual particles were breaking away from the tablet. For PH101/CCS (<xref ref-type="fig" rid="pharmaceutics-15-00489-f007">Figure 7</xref>c), the porosity of the wetted volume increased rapidly in the first three seconds. This was attributed to the fast swelling of CCS particles, resulting in a rapid increase in porosity close to the surface of the tablets. The changes in porosity were caused by particles’ movement. The changed in porosity along with the swelling of individual particles caused an increase in the tablet volume.</p>
          <p>Unsurprisingly, the interparticle forces calculated in the DEM were strongly affected by the swelling process (<xref ref-type="fig" rid="pharmaceutics-15-00489-f007">Figure 7</xref>b,d). The swelling exerted stress on the particles, which caused an increase in the interparticle forces. The stress will reach a maximum, which then would lead to the disintegration of the tablet. The interparticle forces rose faster with increasing porosity (<xref ref-type="fig" rid="pharmaceutics-15-00489-f007">Figure 7</xref>b). For PH101/CCS (<xref ref-type="fig" rid="pharmaceutics-15-00489-f007">Figure 7</xref>d), the tablets with the two lower CCS concentrations had the same force profile, while the tablet with <inline-formula><mml:math id="mm101"><mml:semantics><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub><mml:mtext> </mml:mtext><mml:mo>=</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> 8% experienced a slower increase of the interparticle force.</p>
          <p><xref ref-type="fig" rid="pharmaceutics-15-00489-f008">Figure 8</xref> shows the pore size (pore body) distributions (PSDs) of the tablets at different time points during the swelling process. As expected, the initial average pore size was larger for tablets with a higher initial porosity, <inline-formula><mml:math id="mm102"><mml:semantics><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>, i.e., a lower compaction pressure resulted in bigger pores. The initial pore size of the PH101/CCS tablets was in the same range as the PH101 tablets. PH101/CCS with <inline-formula><mml:math id="mm103"><mml:semantics><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> 2% tablets had similar PSDs as tablets with <inline-formula><mml:math id="mm104"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula>, as both had approximately the same initial porosity, and the initial PSD was primarily driven by the PH101 as the major component in the tablet. As expected for the tablet with a higher CCS content, <inline-formula><mml:math id="mm105"><mml:semantics><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> 5% and 8%, the number of smaller pores (∼10 <inline-formula><mml:math id="mm106"><mml:semantics><mml:mi mathvariant="sans-serif">μ</mml:mi></mml:semantics></mml:math></inline-formula>m) was higher than for <inline-formula><mml:math id="mm107"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 2%. For all tablets, the pore size increased over time, and the pores opened up shortly before the break-up of the tablet. At the maximum swelling capacity, there were pores &gt;70 <inline-formula><mml:math id="mm108"><mml:semantics><mml:mi mathvariant="sans-serif">μ</mml:mi></mml:semantics></mml:math></inline-formula>m, which were not present at the two previous time points.</p>
          <p>Cumulative porosity maps were generated to analyse the pore space spatially. This method is described in detail in [<xref ref-type="bibr" rid="B38-pharmaceutics-15-00489">38</xref>]. In brief, PoreSpy [<xref ref-type="bibr" rid="B39-pharmaceutics-15-00489">39</xref>] was used to generate a 3D voxel image of the tablet based on particles’ position and radius. A cuboid subsection (1400 × 1400 × 800 <inline-formula><mml:math id="mm109"><mml:semantics><mml:mi mathvariant="sans-serif">μ</mml:mi></mml:semantics></mml:math></inline-formula>m<inline-formula><mml:math id="mm110"><mml:semantics><mml:msup><mml:mrow/><mml:mn>3</mml:mn></mml:msup></mml:semantics></mml:math></inline-formula>) of the voxel image at the centre of the tablet was selected for this analysis. The maps were obtained by dividing the sum of the number of voxels classified as voids along each dimension (<italic>x</italic>, <italic>y</italic>, and <italic>z</italic>) by the total number of voxels per dimension. The generated maps depict the void fraction at each position. These maps were obtained for different time instances during the swelling process (<xref ref-type="fig" rid="pharmaceutics-15-00489-f009">Figure 9</xref> and <xref ref-type="fig" rid="pharmaceutics-15-00489-f010">Figure 10</xref>).</p>
          <p>As the liquid moves in one direction from the top to the bottom, resulting in the swelling of the particles from top to bottom, it is expected that the porosity will also mostly be affected along the <italic>z</italic> direction. However, it can be observed that the porosity changed across the entire tablet, though it had not been fully wetted.</p>
          <p>The cumulative porosity analysis highlighted that the porosity was higher on the edges during the swelling process, which indicates that the tablet began to break up from the edges. For the PH101 tablets with <inline-formula><mml:math id="mm111"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>10</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> and <inline-formula><mml:math id="mm112"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula>, the trend in the porosity distribution was similar across the entire tablet, while for PH101, <inline-formula><mml:math id="mm113"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>22</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula>, the porosity was significantly higher on the edges compared to the tablet centre.</p>
          <p>The cumulative porosity maps for the PH101/CCS tablets were similar at the initial and the halfway times. The porosity was slightly higher at the edges for PH101/CCS, <inline-formula><mml:math id="mm114"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%, at the halfway point. At the final time, where the tablets reached their maximum swelling capacity, the porosity at areas close to the surface increased with increasing CCS content. This was in contrast to the overall swelling and disintegration of these tablets, where <inline-formula><mml:math id="mm115"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8% was the tablet with the slowest swelling, i.e., the time to reach the maximum normalised swelling capacity. The disintegration of the <inline-formula><mml:math id="mm116"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8% tablet was, therefore, not controlled by the swelling of the tablet, but the liquid uptake process, which is further discussed below. This slower liquid uptake means that a smaller number of particles were swelling for the <inline-formula><mml:math id="mm117"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8% tablet, which in turn resulted in a slower change of the interparticle forces for this case compared to the lower CCS concentrations.</p>
        </sec>
        <sec id="sec3dot3dot2-pharmaceutics-15-00489">
          <title>3.3.2. Pore Space behind the Liquid Front</title>
          <p>Both experiments and simulations showed a slower swelling rate for the tablet with the highest CCS content (<inline-formula><mml:math id="mm118"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%) (see <xref ref-type="fig" rid="pharmaceutics-15-00489-f006">Figure 6</xref>). These tablets also had the slowest liquid penetration rate. A similar trend was observed by [<xref ref-type="bibr" rid="B41-pharmaceutics-15-00489">41</xref>,<xref ref-type="bibr" rid="B42-pharmaceutics-15-00489">42</xref>], who showed that the disintegration time is prolonged with higher CCS content. As the liquid penetration rate is directly linked to the pore size, it is crucial to understand how the pore size changes in the wetted domain, as well as in the dry domain of the tablet.</p>
          <p>The average pore size of the wetted domain of PH101/CCS, <inline-formula><mml:math id="mm119"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%, decreased during the initial stages of the swelling (<xref ref-type="fig" rid="pharmaceutics-15-00489-f011">Figure 11</xref>a). The pore size of PH101/CCS, <inline-formula><mml:math id="mm120"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 5%, slightly decreased initially, whereas PH101/CCS <inline-formula><mml:math id="mm121"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 2% was constantly increasing. Reference [<xref ref-type="bibr" rid="B30-pharmaceutics-15-00489">30</xref>] explained that the reason for the decrease in the pore size (porosity) was due to the swelling of particles being much faster than that particle contacts could dissipate their potential energy. Therefore, the particle movement would be limited and the particle packing would clog (i.e., the porosity would tend to decrease). The decrease in average pore size is an indication that the pores were closing, which reduces the liquid flow. The decrease in the pore size behind the liquid front could be observed across all formulations, but it was most significant (&gt;30% reduction in pore size) for the tablets with <inline-formula><mml:math id="mm122"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%. Interestingly, the pore size reduction had a nonlinear dependence on the liquid penetration depth. CCS swelled significantly faster compared to PH101, causing the closing of the pore space, which reduced the liquid flow into the tablet.</p>
        </sec>
        <sec id="sec3dot3dot3-pharmaceutics-15-00489">
          <title>3.3.3. Pore Space Ahead of Liquid Front</title>
          <p>As the particle swelling of the material studied was omnidirectional, it can affect the dry volume of the tablet. A change in the pore space of the dry volume impacts the liquid penetration rate, which is mostly driven by the capillary action. The capillary pressure depends on the pore size at the liquid front, i.e., at the interface of the wetted and the dry volume.</p>
          <p>The pore space of the wetted and dry volume can be analysed through the pore size ratio (PS/PS<inline-formula><mml:math id="mm123"><mml:semantics><mml:msub><mml:mrow/><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>) across the tablet height at different liquid front positions (<xref ref-type="fig" rid="pharmaceutics-15-00489-f012">Figure 12</xref>). The focus was on the smaller pores (&lt;30 <inline-formula><mml:math id="mm124"><mml:semantics><mml:mi mathvariant="sans-serif">μ</mml:mi></mml:semantics></mml:math></inline-formula>m), as smaller pores have a greater impact on liquid flow compared to large pores.</p>
          <p>The number of pores decreasing in size at the surface of the tablet was largest for PH101/CCS, <inline-formula><mml:math id="mm125"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%. At three seconds, the small pores of the <inline-formula><mml:math id="mm126"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 5% and <inline-formula><mml:math id="mm127"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 2% tablets were opening up more significantly compared to <inline-formula><mml:math id="mm128"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%. It can also be observed that the dry pores changed in size substantially during the swelling of the wetted volume with a decrease in the size of many small pores. Again, this phenomenon was most significant for the PH101/CCS tablet with <inline-formula><mml:math id="mm129"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%. The reduction in the pore size of the dry pore and wetted pores slowed down the water uptake of these tablets, which resulted in a slower swelling and ultimately delayed disintegration of the entire tablet.</p>
        </sec>
      </sec>
    </sec>
    <sec id="sec4-pharmaceutics-15-00489">
      <title>4. Summary and Conclusions</title>
      <p>This study demonstrated the simulation of tablet swelling by combining DEM with a single-particle swelling model and experimental liquid penetration data. The model captured the difference in the swelling behaviour of the tablets with different porosities and formulations well. For all tablets, the pore size increased over time, and the pores opened up shortly before the break-up of the tablet. Both in the experiments and DEM, the swelling was slower for tablets with the highest disintegrant concentration (PH101/CCS with <inline-formula><mml:math id="mm130"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%) due to the closure of the pores in both the wetted volume and dry volume. The closure of pores hinders the liquid from accessing other particles and slows down the overall swelling process.</p>
      <p>This study provides new insights into the changes in pore space during the disintegration, which is crucial to better understand the impact of porosity and formulations on the performance of tablets. This is particularly important for formulations where the liquid uptake is performance-controlling. The interplay between the formulation, manufacturing conditions, and the dynamic change of the pore space is crucial to make informed decisions during the development of a new drug product. Having a deep understanding of the fundamental changes during the disintegration and dissolution process and its link to the formulation and process conditions can accelerate the development process and increase the robustness of the design process.</p>
      <p>Future work will focus on the incorporation of a liquid penetration model, replacing the current need for experimental data, and a dissolution model to predict drug release as a function of time. The proposed modelling approach should also be tested and validated across a larger number of relevant materials and more complex formulations.</p>
    </sec>
  </body>
  <back>
    <notes>
      <title>Author Contributions</title>
      <p>Conceptualisation, M.S. and D.M.; methodology, M.S. and D.M.; software, M.S. and T.S.; formal analysis, M.S. and M.A.-S.; investigation, M.S. and M.A.-S.; resources, D.M.; data curation, M.S.; writing—original draft preparation, M.S.; writing—review and editing, M.S., M.A.-S., T.S., P.B., J.A.Z., S.M.H., K.P., B.F.J. and D.M.; visualisation, M.S.; supervision, J.A.Z., S.M.H., K.P., B.F.J. and D.M.; project administration, D.M.; funding acquisition, D.M. All authors have read and agreed to the published version of the manuscript.</p>
    </notes>
    <notes>
      <title>Data Availability Statement</title>
      <p>All data underpinning this publication are openly available from the University of Strathclyde KnowledgeBase at <uri>https://doi.org/10.15129/793370a3-78c2-4308-8c0b-beff4e997ade</uri>.</p>
    </notes>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors would like to thank the Scottish Research Partnership in Engineering (<uri>www.srpe.ac.uk</uri>), the Scottish Funding Council (<uri>www.sfc.ac.uk</uri>), and the National Manufacturing Institute Scotland (<uri>www.nmis.scot</uri>) for their support of this work. The authors would like to acknowledge that this work was carried out in the CMAC National Facility supported by the UKRPIF (UK Research Partnership Fund) award from the Higher Education Funding Council for England (HEFCE) (Grant Ref. HH13054). S.M.H. acknowledges support from Deutsche Forschungsgemeinschaft (DFG) (German Research Foundation) under Germany’s Excellence Strategy—EXC 2075-390740016 and from the Stuttgart Center for Simulation Science (SimTech).</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <glossary>
      <title>Abbreviations</title>
      <p>The following abbreviations are used in this manuscript:
      <array><tbody><tr><td align="left" valign="middle">API</td><td align="left" valign="middle">Active pharmaceutical ingredient</td></tr><tr><td align="left" valign="middle">CCS</td><td align="left" valign="middle">Croscarmellose sodium</td></tr><tr><td align="left" valign="middle">DEM</td><td align="left" valign="middle">Discrete element method</td></tr><tr><td align="left" valign="middle">MCC</td><td align="left" valign="middle">Microcrystalline cellulose</td></tr><tr><td align="left" valign="middle">PH101</td><td align="left" valign="middle">Microcrystalline cellulose Avicel PH101</td></tr><tr><td align="left" valign="middle">SAP</td><td align="left" valign="middle">Superabsorbent polymer particles</td></tr><tr><td align="left" valign="middle">THz</td><td align="left" valign="middle">Terahertz</td></tr><tr><td align="left" valign="middle">TPI</td><td align="left" valign="middle">Terahertz-pulsed imaging</td></tr></tbody></array></p>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="B1-pharmaceutics-15-00489">
        <label>1.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Indurkhya</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Abed</surname>
              <given-names>S.N.</given-names>
            </name>
            <name>
              <surname>Shnoudeh</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Maheshwari</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Deb</surname>
              <given-names>P.K.</given-names>
            </name>
            <name>
              <surname>Tekade</surname>
              <given-names>R.K.</given-names>
            </name>
          </person-group>
          <article-title>Chapter 6—Influence of Drug Properties and Routes of Drug Administration on the Design of Controlled Release System</article-title>
          <source>Dosage Form Design Considerations</source>
          <person-group person-group-type="editor">
            <name>
              <surname>Tekade</surname>
              <given-names>R.K.</given-names>
            </name>
          </person-group>
          <comment>Advances in Pharmaceutical Product Development and Research</comment>
          <publisher-name>Academic Press</publisher-name>
          <publisher-loc>Cambrigde, MA, USA</publisher-loc>
          <year>2018</year>
          <fpage>179</fpage>
          <lpage>223</lpage>
        </element-citation>
      </ref>
      <ref id="B2-pharmaceutics-15-00489">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugimori</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Compaction Process of Pharmaceutical Tablets</article-title>
          <source>J. Soc. Powder Technol. Jpn.</source>
          <year>2015</year>
          <volume>52</volume>
          <fpage>345</fpage>
          <lpage>352</lpage>
          <pub-id pub-id-type="doi">10.4164/sptj.52.345</pub-id>
        </element-citation>
      </ref>
      <ref id="B3-pharmaceutics-15-00489">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kadiri</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Michrafy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Dodds</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Pharmaceutical powders compaction: Experimental and numerical analysis of the density distribution</article-title>
          <source>Powder Technol.</source>
          <year>2005</year>
          <volume>157</volume>
          <fpage>176</fpage>
          <lpage>182</lpage>
          <pub-id pub-id-type="doi">10.1016/j.powtec.2005.05.025</pub-id>
        </element-citation>
      </ref>
      <ref id="B4-pharmaceutics-15-00489">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cunningham</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sinka</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Zavaliangos</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Analysis of tablet compaction. I. Characterization of mechanical behavior of powder and powder/tooling friction</article-title>
          <source>J. Pharm. Sci.</source>
          <year>2004</year>
          <volume>93</volume>
          <fpage>2022</fpage>
          <lpage>2039</lpage>
          <pub-id pub-id-type="doi">10.1002/jps.20110</pub-id>
          <pub-id pub-id-type="pmid">15236452</pub-id>
        </element-citation>
      </ref>
      <ref id="B5-pharmaceutics-15-00489">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>C.Y.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Mills</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bentham</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Best</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Numerical and experimental investigation of capping mechanisms during pharmaceutical tablet compaction</article-title>
          <source>Powder Technol.</source>
          <year>2008</year>
          <volume>181</volume>
          <fpage>121</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="doi">10.1016/j.powtec.2006.12.017</pub-id>
        </element-citation>
      </ref>
      <ref id="B6-pharmaceutics-15-00489">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markl</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zeitler</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>A Review of Disintegration Mechanisms and Measurement Techniques</article-title>
          <source>Pharm. Res.</source>
          <year>2017</year>
          <volume>34</volume>
          <fpage>890</fpage>
          <lpage>917</lpage>
          <pub-id pub-id-type="doi">10.1007/s11095-017-2129-z</pub-id>
          <pub-id pub-id-type="pmid">28251425</pub-id>
        </element-citation>
      </ref>
      <ref id="B7-pharmaceutics-15-00489">
        <label>7.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>York</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Design of dosage forms</article-title>
          <source>Aulton’s Pharmaceutics the Design and Manufacture of Medicines</source>
          <edition>6th ed.</edition>
          <person-group person-group-type="editor">
            <name>
              <surname>Aulton</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>K.M.G.</given-names>
            </name>
          </person-group>
          <publisher-name>Elsevier</publisher-name>
          <publisher-loc>Amsterdam, The Netherlands</publisher-loc>
          <year>2022</year>
          <comment>Chapter 1</comment>
          <fpage>1</fpage>
          <lpage>12</lpage>
        </element-citation>
      </ref>
      <ref id="B8-pharmaceutics-15-00489">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Sharabi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Markl</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mudley</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Bawuah</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Karttunen</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Ridgway</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gane</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Ketolainen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Peiponen</surname>
              <given-names>K.E.</given-names>
            </name>
            <name>
              <surname>Rades</surname>
              <given-names>T.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Simultaneous investigation of the liquid transport and swelling performance during tablet disintegration</article-title>
          <source>Int. J. Pharm.</source>
          <year>2020</year>
          <volume>584</volume>
          <fpage>119380</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119380</pub-id>
        </element-citation>
      </ref>
      <ref id="B9-pharmaceutics-15-00489">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalaria</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>G.K.</given-names>
            </name>
            <name>
              <surname>Laru</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>An industrial approach towards solid dosage development for first-in-human studies: Application of predictive science and lean principles</article-title>
          <source>Drug Discov. Today</source>
          <year>2020</year>
          <volume>25</volume>
          <fpage>505</fpage>
          <lpage>518</lpage>
          <pub-id pub-id-type="doi">10.1016/j.drudis.2019.12.012</pub-id>
        </element-citation>
      </ref>
      <ref id="B10-pharmaceutics-15-00489">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wren</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Linking Dissolution to Disintegration in Immediate Release Tablets Using Image Analysis and a Population Balance Modelling Approach</article-title>
          <source>Pharm. Res.</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>198</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="doi">10.1007/s11095-011-0535-1</pub-id>
        </element-citation>
      </ref>
      <ref id="B11-pharmaceutics-15-00489">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masoodi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Pillai</surname>
              <given-names>K.M.</given-names>
            </name>
          </person-group>
          <article-title>Darcy’s Law-Based Model for Wicking in Paper-Like Swelling Porous Media</article-title>
          <source>Am. Inst. Chem. Eng. J.</source>
          <year>2010</year>
          <volume>59</volume>
          <fpage>2257</fpage>
          <lpage>2267</lpage>
          <pub-id pub-id-type="doi">10.1002/aic.12163</pub-id>
        </element-citation>
      </ref>
      <ref id="B12-pharmaceutics-15-00489">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markl</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Yassin</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>D.I.</given-names>
            </name>
            <name>
              <surname>Goodwin</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zeitler</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Mathematical modelling of liquid transport in swelling pharmaceutical immediate release tablets</article-title>
          <source>Int. J. Pharm.</source>
          <year>2017</year>
          <volume>526</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.04.015</pub-id>
        </element-citation>
      </ref>
      <ref id="B13-pharmaceutics-15-00489">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schott</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Kinetics of swelling of polymers and their gels</article-title>
          <source>J. Pharm. Sci.</source>
          <year>1992</year>
          <volume>81</volume>
          <fpage>467</fpage>
          <lpage>470</lpage>
          <pub-id pub-id-type="doi">10.1002/jps.2600810516</pub-id>
          <pub-id pub-id-type="pmid">1403682</pub-id>
        </element-citation>
      </ref>
      <ref id="B14-pharmaceutics-15-00489">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>De Simone</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Koorapaty</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Calibration and verification of DEM parameters for the quantitative simulation of pharmaceutical powder compression process</article-title>
          <source>Powder Technol.</source>
          <year>2021</year>
          <volume>378</volume>
          <fpage>160</fpage>
          <lpage>171</lpage>
          <pub-id pub-id-type="doi">10.1016/j.powtec.2020.09.019</pub-id>
        </element-citation>
      </ref>
      <ref id="B15-pharmaceutics-15-00489">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garner</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Strong</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zavaliangos</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Study of the die compaction of powders to high relative densities using the discrete element method</article-title>
          <source>Powder Technol.</source>
          <year>2018</year>
          <volume>330</volume>
          <fpage>357</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="doi">10.1016/j.powtec.2018.02.015</pub-id>
        </element-citation>
      </ref>
      <ref id="B16-pharmaceutics-15-00489">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Persson</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Frenning</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>An experimental evaluation of the accuracy to simulate granule bed compression using the discrete element method</article-title>
          <source>Powder Technol.</source>
          <year>2012</year>
          <volume>219</volume>
          <fpage>249</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="doi">10.1016/j.powtec.2011.12.054</pub-id>
        </element-citation>
      </ref>
      <ref id="B17-pharmaceutics-15-00489">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Persson</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Frenning</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>An experimental evaluation of discrete element simulations of confined powder compression using an extended truncated-sphere model</article-title>
          <source>Powder Technol.</source>
          <year>2015</year>
          <volume>284</volume>
          <fpage>257</fpage>
          <lpage>264</lpage>
          <pub-id pub-id-type="doi">10.1016/j.powtec.2015.06.053</pub-id>
        </element-citation>
      </ref>
      <ref id="B18-pharmaceutics-15-00489">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haustein</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gladkyy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schwarze</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Discrete element modeling of deformable particles in YADE</article-title>
          <source>SoftwareX</source>
          <year>2017</year>
          <volume>6</volume>
          <fpage>118</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="doi">10.1016/j.softx.2017.05.001</pub-id>
        </element-citation>
      </ref>
      <ref id="B19-pharmaceutics-15-00489">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thakur</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Ahmadian</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ooi</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>An experimental and numerical study of packing, compression, and caking behaviour of detergent powders</article-title>
          <source>Particuology</source>
          <year>2014</year>
          <volume>12</volume>
          <fpage>2</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1016/j.partic.2013.06.009</pub-id>
        </element-citation>
      </ref>
      <ref id="B20-pharmaceutics-15-00489">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nordstrm</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Alderborn</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Frenning</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Compressibility and tablet forming ability of bimodal granule mixtures: Experiments and DEM simulations</article-title>
          <source>Int. J. Pharm.</source>
          <year>2018</year>
          <volume>540</volume>
          <fpage>120</fpage>
          <lpage>131</lpage>
        </element-citation>
      </ref>
      <ref id="B21-pharmaceutics-15-00489">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ketterhagen</surname>
              <given-names>W.R.</given-names>
            </name>
            <name>
              <surname>am Ende</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>B.C.</given-names>
            </name>
          </person-group>
          <article-title>Process Modeling in the Pharmaceutical Industry using the Discrete Element Method</article-title>
          <source>J. Pharm. Sci.</source>
          <year>2009</year>
          <volume>98</volume>
          <fpage>442</fpage>
          <lpage>470</lpage>
          <pub-id pub-id-type="doi">10.1002/jps.21466</pub-id>
        </element-citation>
      </ref>
      <ref id="B22-pharmaceutics-15-00489">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luding</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Introduction to discrete element methods Basic of contact force models and how to perform the micro-macro transition to continuum theory</article-title>
          <source>Eur. J. Environ. Civ. Eng.</source>
          <year>2008</year>
          <volume>12</volume>
          <fpage>785</fpage>
          <lpage>826</lpage>
          <pub-id pub-id-type="doi">10.1080/19648189.2008.9693050</pub-id>
        </element-citation>
      </ref>
      <ref id="B23-pharmaceutics-15-00489">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Storkers</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Biwa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Larsson</surname>
              <given-names>P.L.</given-names>
            </name>
          </person-group>
          <article-title>Similarity analysis of inelastic contact</article-title>
          <source>Int. J. Solids Struct.</source>
          <year>1997</year>
          <volume>34</volume>
          <fpage>3061</fpage>
          <lpage>3083</lpage>
        </element-citation>
      </ref>
      <ref id="B24-pharmaceutics-15-00489">
        <label>24.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <source>Contact Mechanics</source>
          <publisher-name>Cambridge University Press</publisher-name>
          <publisher-loc>Cambridge, UK</publisher-loc>
          <year>1987</year>
        </element-citation>
      </ref>
      <ref id="B25-pharmaceutics-15-00489">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toson</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Doshi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Matic</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Siegmann</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Blackwood</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brandon</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wilsdon</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kimber</surname>
              <given-names>J.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Continuous mixing technology: Validation of a DEM model</article-title>
          <source>Int. J. Pharm.</source>
          <year>2021</year>
          <volume>608</volume>
          <fpage>121065</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121065</pub-id>
          <pub-id pub-id-type="pmid">34481005</pub-id>
        </element-citation>
      </ref>
      <ref id="B26-pharmaceutics-15-00489">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kimber</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kazarian</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Stepanek</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Modelling of pharmaceutical tablet swelling and dissolution using discrete element method</article-title>
          <source>Chem. Eng. Sci.</source>
          <year>2012</year>
          <volume>69</volume>
          <fpage>394</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ces.2011.10.066</pub-id>
        </element-citation>
      </ref>
      <ref id="B27-pharmaceutics-15-00489">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalný</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Grof</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Štěpánek</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Microstructure based simulation of the disintegration and dissolution of immediate release pharmaceutical tablets</article-title>
          <source>Powder Technol.</source>
          <year>2021</year>
          <volume>377</volume>
          <fpage>257</fpage>
          <lpage>268</lpage>
          <pub-id pub-id-type="doi">10.1016/j.powtec.2020.08.093</pub-id>
        </element-citation>
      </ref>
      <ref id="B28-pharmaceutics-15-00489">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schtt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Stamatopoulos</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Batchelor</surname>
              <given-names>H.K.</given-names>
            </name>
            <name>
              <surname>Simmons</surname>
              <given-names>M.J.H.</given-names>
            </name>
            <name>
              <surname>Alexiadis</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Modelling and Simulation of the Drug Release from a Solid Dosage Form in the Human Ascending Colon: The Influence of Different Motility Patterns and Fluid Viscosities</article-title>
          <source>Pharmaceutics</source>
          <year>2021</year>
          <volume>13</volume>
          <fpage>859</fpage>
        </element-citation>
      </ref>
      <ref id="B29-pharmaceutics-15-00489">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sweijen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Chareyre</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hassanizadeh</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Karadimitriou</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Grain-scale modelling of swelling granular materials; application to super absorbent polymers</article-title>
          <source>Powder Technol.</source>
          <year>2017</year>
          <volume>318</volume>
          <fpage>411</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="doi">10.1016/j.powtec.2017.06.015</pub-id>
        </element-citation>
      </ref>
      <ref id="B30-pharmaceutics-15-00489">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sweijen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hassanizadeh</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Chareyre</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Unsaturated flow in a packing of swelling particles; a grain-scale model</article-title>
          <source>Adv. Water Resour.</source>
          <year>2020</year>
          <volume>142</volume>
          <fpage>103642</fpage>
          <pub-id pub-id-type="doi">10.1016/j.advwatres.2020.103642</pub-id>
        </element-citation>
      </ref>
      <ref id="B31-pharmaceutics-15-00489">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braile</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hare</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>C.Y.</given-names>
            </name>
          </person-group>
          <article-title>DEM analysis of swelling behaviour in granular media</article-title>
          <source>Adv. Powder Technol.</source>
          <year>2022</year>
          <volume>33</volume>
          <fpage>103806</fpage>
          <pub-id pub-id-type="doi">10.1016/j.apt.2022.103806</pub-id>
        </element-citation>
      </ref>
      <ref id="B32-pharmaceutics-15-00489">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soundaranathan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vivattanaseth</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Pitt</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Markl</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Quantification of swelling characteristics of pharmaceutical particles</article-title>
          <source>Int. J. Pharm.</source>
          <year>2020</year>
          <volume>590</volume>
          <fpage>119903</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119903</pub-id>
        </element-citation>
      </ref>
      <ref id="B33-pharmaceutics-15-00489">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Sharabi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Markl</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Vivacqua</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Bawuah</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>MacLean</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Bentley</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>York</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Marigo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zeitler</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Terahertz pulsed imaging as a new method for investigating the liquid transport kinetics of <italic>α</italic>-alumina powder compacts</article-title>
          <source>Chem. Eng. Res. Des.</source>
          <year>2021</year>
          <volume>165</volume>
          <fpage>386</fpage>
          <lpage>397</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cherd.2020.11.006</pub-id>
        </element-citation>
      </ref>
      <ref id="B34-pharmaceutics-15-00489">
        <label>34.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Smilauer</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Angelidakis</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Catalano</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Caulk</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Chareyre</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Dorofeenko</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Duriez</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Dyck</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Er</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Eulitz</surname>
              <given-names>A.</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Yade Documentation</source>
          <edition>3rd ed.</edition>
          <comment>The Yade Project</comment>
          <year>2021</year>
          <comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://yade-dem.org/doc/" ext-link-type="uri">http://yade-dem.org/doc/</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2022-11-29">(accessed on 29 November 2022)</date-in-citation>
          <pub-id pub-id-type="doi">10.5281/zenodo.5705394</pub-id>
        </element-citation>
      </ref>
      <ref id="B35-pharmaceutics-15-00489">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suryadi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sutriyo</surname>
            </name>
            <name>
              <surname>Angeline</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Murti</surname>
              <given-names>M.W.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of Microcrystalline Cellulose Obtained from Enzymatic Hydrolysis of Alpha-Cellulose and its Application</article-title>
          <source>J. Young Pharm.</source>
          <year>2018</year>
          <volume>10</volume>
          <fpage>87</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.5530/jyp.2018.2s.17</pub-id>
        </element-citation>
      </ref>
      <ref id="B36-pharmaceutics-15-00489">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huyghe</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>J.D.</given-names>
            </name>
          </person-group>
          <article-title>Quaadrif Hasic Mechanics of Swelling Incompressible porous media</article-title>
          <source>Int. J. Eng. Sci.</source>
          <year>1997</year>
          <volume>35</volume>
          <fpage>793</fpage>
          <lpage>802</lpage>
          <pub-id pub-id-type="doi">10.1016/S0020-7225(96)00119-X</pub-id>
        </element-citation>
      </ref>
      <ref id="B37-pharmaceutics-15-00489">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chareyre</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Cortis</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Catalano</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Barthelemy</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Pore-Scale Modeling of Viscous Flow and Induced Forces in Dense Sphere Packings</article-title>
          <source>Transp. Porous Media</source>
          <year>2012</year>
          <volume>94</volume>
          <fpage>595</fpage>
          <lpage>615</lpage>
          <pub-id pub-id-type="doi">10.1007/s11242-012-0057-2</pub-id>
        </element-citation>
      </ref>
      <ref id="B38-pharmaceutics-15-00489">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markl</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Strobel</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schlossnikl</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bøtker</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bawuah</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Ridgway</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rantanen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rades</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gane</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Peiponen</surname>
              <given-names>K.E.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Characterisation of pore structures of pharmaceutical tablets: A review</article-title>
          <source>Int. J. Pharm.</source>
          <year>2018</year>
          <volume>538</volume>
          <fpage>188</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.01.017</pub-id>
        </element-citation>
      </ref>
      <ref id="B39-pharmaceutics-15-00489">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gostick</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>Z.A.</given-names>
            </name>
            <name>
              <surname>Tranter</surname>
              <given-names>T.G.</given-names>
            </name>
            <name>
              <surname>Kok</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Agnaou</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sadeghi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jervis</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>PoreSpy: A Python Toolkit for Quantitative Analysis of Porous Media Images</article-title>
          <source>J. Open Source Softw.</source>
          <year>2019</year>
          <volume>4</volume>
          <fpage>1296</fpage>
          <pub-id pub-id-type="doi">10.21105/joss.01296</pub-id>
        </element-citation>
      </ref>
      <ref id="B40-pharmaceutics-15-00489">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nystrrm</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Alderborn</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Duberg</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Karehill</surname>
              <given-names>P.G.</given-names>
            </name>
          </person-group>
          <article-title>Bonding Surface area and Bonding Mechanism-Two Important Factors fir the Understanding of Powder Comparability</article-title>
          <source>Drug Dev. Ind. Pharm.</source>
          <year>1993</year>
          <volume>19</volume>
          <fpage>2143</fpage>
          <lpage>2196</lpage>
        </element-citation>
      </ref>
      <ref id="B41-pharmaceutics-15-00489">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berardi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bisharat</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Blaibleh</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pavoni</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Cespi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A Simple and Inexpensive Image Analysis Technique to Study the Effect of Disintegrants Concentration and Diluents Type on Disintegration</article-title>
          <source>J. Pharm. Sci.</source>
          <year>2018</year>
          <volume>107</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1016/j.xphs.2018.06.008</pub-id>
        </element-citation>
      </ref>
      <ref id="B42-pharmaceutics-15-00489">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maclean</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Soundaranathan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Khadra</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Markl</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Exploring the performance-controlling tablet disintegration mechanisms for direct compression formulations</article-title>
          <source>Int. J. Pharm.</source>
          <year>2021</year>
          <volume>599</volume>
          <fpage>120221</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120221</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec sec-type="display-objects">
      <title>Figures and Tables</title>
      <fig id="pharmaceutics-15-00489-f001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>A schematic of the (<bold>a</bold>) experimental and (<bold>b</bold>) DEM modelling domain.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g001.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f002" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Work flow of the tablet swelling and break-up model. A single-particle model, DEM tablet compaction model, and experimental liquid penetration data are combined to model the swelling and break-up process.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g002.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f003" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Flow chart for simulating tablet swelling using DEM incorporating a single-particle swelling model and experimental liquid penetration data.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g003.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f004" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Experimental compression profile of (<bold>a</bold>) MCC PH101 tablet with porosities of 10%, 15%, and 22% and (<bold>b</bold>) MCC PH101 and CCS tablet of <inline-formula><mml:math id="mm131"><mml:semantics><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub><mml:mtext> </mml:mtext><mml:mo>=</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> 2, 5, and 8 compared with MCC PH101 tablet with a porosity of 15%.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g004.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f005" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Comparison of experimental and DEM compression profiles. (<bold>a</bold>) Full compression profile of MCC PH101 tablet with a porosity of 15%. (<bold>b</bold>) Loading profile of MCC PH101 tablet with a porosity of 15% with scaled (to correct for the initial difference in porosity between experiment and DEM) porosity used for DEM parameter estimation. The validation data are shown in (<bold>c</bold>) for MCC PH101 <inline-formula><mml:math id="mm132"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>22</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula> and (<bold>d</bold>) for PH101/CCS with <inline-formula><mml:math id="mm133"><mml:semantics><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:semantics></mml:math></inline-formula>%.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g005.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f006" position="float">
        <label>Figure 6</label>
        <caption>
          <p>Analysis of the DEM simulation of PH101 tablets and comparison to experimental results, normalised swelling by height, as a function of normalised time, <inline-formula><mml:math id="mm134"><mml:semantics><mml:msup><mml:mi>T</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:semantics></mml:math></inline-formula>. (<bold>a</bold>) PH101 tablets; (<bold>b</bold>) PH101/CCS tablets. The solid line and shaded area correspond to the average and standard deviation, respectively, of three samples (two for PH101/CCS, <inline-formula><mml:math id="mm135"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 5%).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g006.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f007" position="float">
        <label>Figure 7</label>
        <caption>
          <p>DEM simulation results. (<bold>a</bold>) PH101 tablets’ porosity for the whole tablet and for the wetted volume only. (<bold>b</bold>) Interparticle forces for PH101 tablets. (<bold>c</bold>) PH101/CCS tablets’ porosity analysed for the whole tablet and for the wetted volume only. (<bold>d</bold>) Interparticle forces for PH101/CCS tablets.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g007.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f008" position="float">
        <label>Figure 8</label>
        <caption>
          <p>Pore size distribution at different time points during swelling of the tablet. (<bold>a</bold>) PH101, <inline-formula><mml:math id="mm136"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>10</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula>. (<bold>b</bold>) PH101, <inline-formula><mml:math id="mm137"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula>. (<bold>c</bold>) PH101, <inline-formula><mml:math id="mm138"><mml:semantics><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>22</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:semantics></mml:math></inline-formula>. (<bold>d</bold>) PH101/CCS, <inline-formula><mml:math id="mm139"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 2%. (<bold>e</bold>) PH101/CCS, <inline-formula><mml:math id="mm140"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 5%. (<bold>f</bold>) PH101/CCS, <inline-formula><mml:math id="mm141"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%. The time points analysed: starting point (0 s), halfway point of reaching maximum swelling capacity and at the time point of maximum swelling capacity.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g008.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f009" position="float">
        <label>Figure 9</label>
        <caption>
          <p>Cumulative porosity maps of the tablet at three different time points during the swelling process of PH101 tablets: Initially, halfway of reaching maximum swelling capacity and maximum swelling capacity. The cuboid subsection has a size of 1400 × 1400 × 800 pixels and was selected at the centre of the tablet for this analysis.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g009.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f010" position="float">
        <label>Figure 10</label>
        <caption>
          <p>Cumulative porosity maps of the tablet at three different time points during the swelling process of PH101/CCS tablets. The cuboid subsection has a size of 1400 × 1400 × 800 pixels and was selected at the centre of the tablet for this analysis.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g010.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f011" position="float">
        <label>Figure 11</label>
        <caption>
          <p>Pore size analysis of the wetted volume for PH101/CCS tablets. (<bold>a</bold>) The average pore size of PH101/CCS tablets at different time points during swelling. (<bold>b</bold>) The pore size ratio (PS/PS<inline-formula><mml:math id="mm142"><mml:semantics><mml:msub><mml:mrow/><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>) of the pores placed up to 0.2 mm behind the liquid front as a function of the liquid penetration depth. PS is the pore size at time t, and PS<inline-formula><mml:math id="mm143"><mml:semantics><mml:msub><mml:mrow/><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> is the pore size at <inline-formula><mml:math id="mm144"><mml:semantics><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:semantics></mml:math></inline-formula> s.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g011.tif"/>
      </fig>
      <fig id="pharmaceutics-15-00489-f012" position="float">
        <label>Figure 12</label>
        <caption>
          <p>The pore size ratio (PS/PS<inline-formula><mml:math id="mm145"><mml:semantics><mml:msub><mml:mrow/><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>) as a function of tablet height focusing on pores &lt;30 <inline-formula><mml:math id="mm146"><mml:semantics><mml:mi mathvariant="sans-serif">μ</mml:mi></mml:semantics></mml:math></inline-formula>m during swelling at 1 s and 3 s. The black vertical line in each plot indicates the liquid front at that particular time point. PS is the pore size at time t, and PS<inline-formula><mml:math id="mm147"><mml:semantics><mml:msub><mml:mrow/><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> is the pore size at <inline-formula><mml:math id="mm148"><mml:semantics><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:semantics></mml:math></inline-formula> s.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-00489-g012.tif"/>
      </fig>
      <table-wrap id="pharmaceutics-15-00489-t001" position="float">
        <object-id pub-id-type="pii">pharmaceutics-15-00489-t001_Table 1</object-id>
        <label>Table 1</label>
        <caption>
          <p>Values of the particle properties: size (<inline-formula><mml:math id="mm149"><mml:semantics><mml:msub><mml:mi>D</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>), true density (<inline-formula><mml:math id="mm150"><mml:semantics><mml:msub><mml:mi>ϱ</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>), shape (<inline-formula><mml:math id="mm151"><mml:semantics><mml:msub><mml:mi>S</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula>), liquid absorption (<inline-formula><mml:math id="mm152"><mml:semantics><mml:msup><mml:mi>Q</mml:mi><mml:mi>max</mml:mi></mml:msup></mml:semantics></mml:math></inline-formula>), and diffusion coefficient (<italic>D</italic>) of the two materials (obtained from [<xref ref-type="bibr" rid="B32-pharmaceutics-15-00489">32</xref>]).</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Material</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm153"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msub><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mstyle></mml:semantics></mml:math></inline-formula> (<inline-formula><mml:math id="mm154"><mml:semantics><mml:mstyle mathvariant="bold"><mml:mi mathvariant="bold-sans-serif">μ</mml:mi></mml:mstyle></mml:semantics></mml:math></inline-formula>m)</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm155"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msub><mml:mi mathvariant="bold-italic">ϱ</mml:mi><mml:mi mathvariant="bold">s</mml:mi></mml:msub></mml:mstyle></mml:semantics></mml:math></inline-formula> (kg/m<inline-formula><mml:math id="mm156"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msup><mml:mrow/><mml:mn>3</mml:mn></mml:msup></mml:mstyle></mml:semantics></mml:math></inline-formula>)</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">
                <inline-formula>
                  <mml:math id="mm157">
                    <mml:semantics>
                      <mml:mstyle mathvariant="bold">
                        <mml:msub>
                          <mml:mi mathvariant="bold-italic">S</mml:mi>
                          <mml:mn>50</mml:mn>
                        </mml:msub>
                      </mml:mstyle>
                    </mml:semantics>
                  </mml:math>
                </inline-formula>
              </th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm158"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msup><mml:mi mathvariant="bold-italic">Q</mml:mi><mml:mi mathvariant="bold">max</mml:mi></mml:msup></mml:mstyle></mml:semantics></mml:math></inline-formula> (g/g)</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><italic>D</italic> (<inline-formula><mml:math id="mm159"><mml:semantics><mml:mstyle mathvariant="bold"><mml:mi mathvariant="bold-sans-serif">μ</mml:mi></mml:mstyle></mml:semantics></mml:math></inline-formula>m<inline-formula><mml:math id="mm160"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msup><mml:mrow/><mml:mn>2</mml:mn></mml:msup></mml:mstyle></mml:semantics></mml:math></inline-formula>/s)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">78 ± 1</td>
              <td align="center" valign="middle">1561 ± 3</td>
              <td align="center" valign="middle">0.73 ± 0.00</td>
              <td align="center" valign="middle">1.45 ± 0.31</td>
              <td align="center" valign="middle">396.39</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">CCS</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">54 ± 1</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">1403 ± 17</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.66 ± 0.01</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">3.16</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">739.75</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="pharmaceutics-15-00489-t002" position="float">
        <object-id pub-id-type="pii">pharmaceutics-15-00489-t002_Table 2</object-id>
        <label>Table 2</label>
        <caption>
          <p>Particle size distribution of the two materials (obtained from [<xref ref-type="bibr" rid="B32-pharmaceutics-15-00489">32</xref>]).</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Material</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm161"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msub><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:mstyle></mml:semantics></mml:math></inline-formula> (<inline-formula><mml:math id="mm162"><mml:semantics><mml:mstyle mathvariant="bold"><mml:mi mathvariant="bold-sans-serif">μ</mml:mi></mml:mstyle></mml:semantics></mml:math></inline-formula>m)</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm163"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msub><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mstyle></mml:semantics></mml:math></inline-formula> (<inline-formula><mml:math id="mm164"><mml:semantics><mml:mstyle mathvariant="bold"><mml:mi mathvariant="bold-sans-serif">μ</mml:mi></mml:mstyle></mml:semantics></mml:math></inline-formula>m)</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm165"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msub><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mn>90</mml:mn></mml:msub></mml:mstyle></mml:semantics></mml:math></inline-formula> (<inline-formula><mml:math id="mm166"><mml:semantics><mml:mstyle mathvariant="bold"><mml:mi mathvariant="bold-sans-serif">μ</mml:mi></mml:mstyle></mml:semantics></mml:math></inline-formula>m)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">45 ± 1</td>
              <td align="center" valign="middle">78 ± 1</td>
              <td align="center" valign="middle">135 ± 1</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">CCS</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">33 ± 1</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">54 ± 1</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">90 ± 1</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="pharmaceutics-15-00489-t003" position="float">
        <object-id pub-id-type="pii">pharmaceutics-15-00489-t003_Table 3</object-id>
        <label>Table 3</label>
        <caption>
          <p>Tablet formulations (PH101 concentration, <inline-formula><mml:math id="mm167"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>PH</mml:mi><mml:mn>101</mml:mn></mml:mrow></mml:msub></mml:semantics></mml:math></inline-formula>; CCS concentration, <inline-formula><mml:math id="mm168"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>), compaction pressure (<inline-formula><mml:math id="mm169"><mml:semantics><mml:mi>σ</mml:mi></mml:semantics></mml:math></inline-formula>), and porosity (<inline-formula><mml:math id="mm170"><mml:semantics><mml:mi>ϵ</mml:mi></mml:semantics></mml:math></inline-formula>) investigated.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Material</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm171"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msub><mml:mi mathvariant="bold-italic">c</mml:mi><mml:mrow><mml:mi mathvariant="bold">PH</mml:mi><mml:mn>101</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:semantics></mml:math></inline-formula> (<inline-formula><mml:math id="mm172"><mml:semantics><mml:mstyle mathvariant="bold"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="bold-italic">w</mml:mi></mml:mrow></mml:mstyle></mml:semantics></mml:math></inline-formula>)</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Material</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm173"><mml:semantics><mml:mstyle mathvariant="bold"><mml:msub><mml:mi mathvariant="bold-italic">c</mml:mi><mml:mi mathvariant="bold">CCS</mml:mi></mml:msub></mml:mstyle></mml:semantics></mml:math></inline-formula> (<inline-formula><mml:math id="mm174"><mml:semantics><mml:mstyle mathvariant="bold"><mml:mrow><mml:mo>%</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">w</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="bold-italic">w</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:semantics></mml:math></inline-formula>)</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm175"><mml:semantics><mml:mstyle mathvariant="bold"><mml:mi mathvariant="bold-italic">σ</mml:mi></mml:mstyle></mml:semantics></mml:math></inline-formula> (MPa)</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin"><inline-formula><mml:math id="mm176"><mml:semantics><mml:mstyle mathvariant="bold"><mml:mi mathvariant="bold-italic">ϵ</mml:mi></mml:mstyle></mml:semantics></mml:math></inline-formula> (%)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">100</td>
              <td align="center" valign="middle">-</td>
              <td align="center" valign="middle">-</td>
              <td align="center" valign="middle">387</td>
              <td align="center" valign="middle">10</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">100</td>
              <td align="center" valign="middle">-</td>
              <td align="center" valign="middle">-</td>
              <td align="center" valign="middle">170</td>
              <td align="center" valign="middle">15</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">100</td>
              <td align="center" valign="middle">-</td>
              <td align="center" valign="middle">-</td>
              <td align="center" valign="middle">105</td>
              <td align="center" valign="middle">22</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">98</td>
              <td align="center" valign="middle">CCS</td>
              <td align="center" valign="middle">2</td>
              <td align="center" valign="middle">162</td>
              <td align="center" valign="middle">15</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">95</td>
              <td align="center" valign="middle">CCS</td>
              <td align="center" valign="middle">5</td>
              <td align="center" valign="middle">162</td>
              <td align="center" valign="middle">15</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">PH101</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">92</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">CCS</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">8</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">158</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">16</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="pharmaceutics-15-00489-t004" position="float">
        <object-id pub-id-type="pii">pharmaceutics-15-00489-t004_Table 4</object-id>
        <label>Table 4</label>
        <caption>
          <p>The number of particles simulated for each formulation.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Formulation</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Number of Particles PH101</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Number of Particles CCS</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">PH101, <inline-formula><mml:math id="mm177"><mml:semantics><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> = 10%</td>
              <td align="center" valign="middle">11,117</td>
              <td align="center" valign="middle">-</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101, <inline-formula><mml:math id="mm178"><mml:semantics><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> = 15%</td>
              <td align="center" valign="middle">10,426</td>
              <td align="center" valign="middle">-</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101, <inline-formula><mml:math id="mm179"><mml:semantics><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> = 22%</td>
              <td align="center" valign="middle">9720</td>
              <td align="center" valign="middle">-</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101/CCS, <inline-formula><mml:math id="mm180"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 2</td>
              <td align="center" valign="middle">10,134</td>
              <td align="center" valign="middle">720</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101/CCS, <inline-formula><mml:math id="mm181"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 5</td>
              <td align="center" valign="middle">9699</td>
              <td align="center" valign="middle">1778</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">PH101/CCS, <inline-formula><mml:math id="mm182"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">9335</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">2828</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="pharmaceutics-15-00489-t005" position="float">
        <object-id pub-id-type="pii">pharmaceutics-15-00489-t005_Table 5</object-id>
        <label>Table 5</label>
        <caption>
          <p>Summary of the DEM parameters used for all simulations. <inline-formula><mml:math id="mm183"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> and <inline-formula><mml:math id="mm184"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> were identified through an optimisation procedure.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Properties</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">
                <inline-formula>
                  <mml:math id="mm185">
                    <mml:semantics>
                      <mml:msub>
                        <mml:mi>k</mml:mi>
                        <mml:mn>1</mml:mn>
                      </mml:msub>
                    </mml:semantics>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" valign="middle">10,000 N/m</td>
            </tr>
            <tr>
              <td align="center" valign="middle">
                <inline-formula>
                  <mml:math id="mm186">
                    <mml:semantics>
                      <mml:mrow>
                        <mml:msub>
                          <mml:mi>k</mml:mi>
                          <mml:mi mathvariant="normal">p</mml:mi>
                        </mml:msub>
                        <mml:mo>/</mml:mo>
                        <mml:msub>
                          <mml:mi>k</mml:mi>
                          <mml:mn>1</mml:mn>
                        </mml:msub>
                      </mml:mrow>
                    </mml:semantics>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" valign="middle">14</td>
            </tr>
            <tr>
              <td align="center" valign="middle">
                <inline-formula>
                  <mml:math id="mm187">
                    <mml:semantics>
                      <mml:mrow>
                        <mml:msub>
                          <mml:mi>k</mml:mi>
                          <mml:mi mathvariant="normal">c</mml:mi>
                        </mml:msub>
                        <mml:mo>/</mml:mo>
                        <mml:msub>
                          <mml:mi>k</mml:mi>
                          <mml:mn>1</mml:mn>
                        </mml:msub>
                      </mml:mrow>
                    </mml:semantics>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" valign="middle">0.1 <sup>1</sup></td>
            </tr>
            <tr>
              <td align="center" valign="middle">
                <inline-formula>
                  <mml:math id="mm188">
                    <mml:semantics>
                      <mml:msub>
                        <mml:mi>ϕ</mml:mi>
                        <mml:mi mathvariant="normal">f</mml:mi>
                      </mml:msub>
                    </mml:semantics>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" valign="middle">0.999 <sup>1</sup></td>
            </tr>
            <tr>
              <td align="center" valign="middle">Simulation time step (<inline-formula><mml:math id="mm189"><mml:semantics><mml:mrow><mml:mo>Δ</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:semantics></mml:math></inline-formula>)</td>
              <td align="center" valign="middle">1 · 10<inline-formula><mml:math id="mm190"><mml:semantics><mml:msup><mml:mrow/><mml:mrow><mml:mo>−</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:msup></mml:semantics></mml:math></inline-formula> s</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Angle of repose, PH101</td>
              <td align="center" valign="middle">0.41 rad <sup>2</sup></td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">Angle of repose, CCS</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.69 rad <sup>3</sup></td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p><sup>1</sup> [<xref ref-type="bibr" rid="B14-pharmaceutics-15-00489">14</xref>]. <sup>2</sup> [<xref ref-type="bibr" rid="B35-pharmaceutics-15-00489">35</xref>]. <sup>3</sup> Measured experimentally.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="pharmaceutics-15-00489-t006" position="float">
        <object-id pub-id-type="pii">pharmaceutics-15-00489-t006_Table 6</object-id>
        <label>Table 6</label>
        <caption>
          <p>Parameters of the power law (<inline-formula><mml:math id="mm191"><mml:semantics><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mi>a</mml:mi><mml:mo>·</mml:mo><mml:msup><mml:mi>t</mml:mi><mml:mi>b</mml:mi></mml:msup></mml:mrow></mml:semantics></mml:math></inline-formula>) describing the experimental liquid penetration depth data.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Properties</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">
                <italic>a</italic>
              </th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">
                <italic>b</italic>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">PH101, <inline-formula><mml:math id="mm192"><mml:semantics><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> = 10%</td>
              <td align="center" valign="middle">0.0535</td>
              <td align="center" valign="middle">0.7313</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101, <inline-formula><mml:math id="mm193"><mml:semantics><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> = 15%</td>
              <td align="center" valign="middle">0.2395</td>
              <td align="center" valign="middle">0.5470</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101, <inline-formula><mml:math id="mm194"><mml:semantics><mml:msub><mml:mi>ϵ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> = 22%</td>
              <td align="center" valign="middle">0.4646</td>
              <td align="center" valign="middle">0.5519</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101/CCS, <inline-formula><mml:math id="mm195"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 2</td>
              <td align="center" valign="middle">0.1871</td>
              <td align="center" valign="middle">0.7339</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101/CCS, <inline-formula><mml:math id="mm196"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 5</td>
              <td align="center" valign="middle">0.1359</td>
              <td align="center" valign="middle">0.8279</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">PH101/CCS, <inline-formula><mml:math id="mm197"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0968</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.8739</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="pharmaceutics-15-00489-t007" position="float">
        <object-id pub-id-type="pii">pharmaceutics-15-00489-t007_Table 7</object-id>
        <label>Table 7</label>
        <caption>
          <p>Calibrated values of loading stiffness <inline-formula><mml:math id="mm198"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:semantics></mml:math></inline-formula> and plastic unloading stiffness limit <inline-formula><mml:math id="mm199"><mml:semantics><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula>.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Properties</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">
                <inline-formula>
                  <mml:math id="mm200">
                    <mml:semantics>
                      <mml:msub>
                        <mml:mi>k</mml:mi>
                        <mml:mn>1</mml:mn>
                      </mml:msub>
                    </mml:semantics>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" valign="middle">10,000 N/m</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">
                <inline-formula>
                  <mml:math id="mm201">
                    <mml:semantics>
                      <mml:msub>
                        <mml:mi>k</mml:mi>
                        <mml:mi mathvariant="normal">p</mml:mi>
                      </mml:msub>
                    </mml:semantics>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" valign="middle" style="border-bottom:solid thin">140,000 N/m</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="pharmaceutics-15-00489-t008" position="float">
        <object-id pub-id-type="pii">pharmaceutics-15-00489-t008_Table 8</object-id>
        <label>Table 8</label>
        <caption>
          <p>Measured and simulated values of the tablet porosity for all conditions investigated.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Formulation</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">Experimental Porosity (%)</th>
              <th align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin">DEM Porosity (%)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">9.5 ± 0.2</td>
              <td align="center" valign="middle">8.2</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">14.6 ± 0.2</td>
              <td align="center" valign="middle">15.3</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101</td>
              <td align="center" valign="middle">22.0 ± 0.3</td>
              <td align="center" valign="middle">22.2</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101/CCS, <inline-formula><mml:math id="mm202"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 2%</td>
              <td align="center" valign="middle">15.1 ± 0.2</td>
              <td align="center" valign="middle">16.7</td>
            </tr>
            <tr>
              <td align="center" valign="middle">PH101/CCS, <inline-formula><mml:math id="mm203"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 5%</td>
              <td align="center" valign="middle">15.5 ± 0.3</td>
              <td align="center" valign="middle">16.9</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">PH101/CCS, <inline-formula><mml:math id="mm204"><mml:semantics><mml:msub><mml:mi>c</mml:mi><mml:mi>CCS</mml:mi></mml:msub></mml:semantics></mml:math></inline-formula> = 8%</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">15.5 ± 0.5</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">17.4</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <fn-group>
      <fn>
        <p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p>
      </fn>
    </fn-group>
  </back>
</article>
